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THE ROLE AND REGULATION OF FAS AND FAS LIGAND IN THE OVARY:
IMPLICATIONS FOR OVARIAN CANCER. Wendi D. Brown, Eva Sapi, and Gil Mor.
Department of Obstetrics and Gynecology, Yale University, School of Medicine, New
Haven, CT.
While ovarian cancer is the leading cause of gynecologic death in the U.S., its
pathogenesis remains unclear. In this study we investigate the expression and regulation
of Fas and FasL in the carcinogenesis of ovarian epithelial cell transformation.
The studies were done using fresh ovarian surgical specimens of varying degrees
of malignancy. Tissues were immediately frozen or used for the in vitro organ culture
system. Organ cultures and ovarian cancer cell lines were grown in the presence or
absence of sex hormones. Fas and FasL expression was determined at the RNA and
protein level by RT-PCR and Western Blot Analysis, respectively. The cells expressing
Fas and FasL were characterized by immunohistochemistry. In addition, estrogen
receptors a and p were identified in the mRNA and protein of the tissue specimens.
The normal, primary, and metastatic ovarian tissue showed a pattern of increasing
FasL expression with increasing severity of the tumor as demonstrated by
immunohistochemistry, RT-PCR, and Western Blot Analysis. Another pattern that
emerged in these samples was the decreasing expression of ER-P with increasing
malignancy. Fas receptor remained the same among these tissues. In the untreated organ
cultures, the inclusion cysts and granulosa layer of the follicle were mildly
immunoreactive for FasL. With the addition of estrogen, there was a general upregulation of FasL expression, especially in the follicular cells. RT-PCR and Western
Blot analysis of the tissue showed a similar result with the largest band detected in the
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estrogen-treated group. Ovarian cancer cell lines showed variable FasL expression in
response to estrogen and tamoxifen stimulation, depending on the type and proportion of
estrogen receptors present.
We propose that the over-expression of FasL by epithelial cells could serve as the
mechanism by which abnormal ovarian surface epithelium could escape immune
surveillance, allowing tumor growth and metastasis and that this event is regulated by
estrogen differentially acting through ER a and (3.
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V. Introduction

V.A.
V.A. 1.

Epithelial Ovarian Cancer
The Epidemiology of Epithelial Ovarian Cancer
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in

the U.S. However, the etiology of this fatal disease remains unknown. Researchers have
identified possible reproductive or environmental factors associated with ovarian cancer
and have implicated various genes in the pathogenesis of this disease, but none have
determined the specific events leading to neoplastic transformation.
The demographic patterns of ovarian cancer have remained stable over the past
few decades. Approximately one in 70 American women will develop ovarian cancer in
her lifetime with an average annual incidence of 15.0 per 100,000 women (26,000 new
cases diagnosed in the U.S. in 1995) (1). This incidence increases with advancing age,
peaking in the eighth decade. The median age at diagnosis is 63, while it is infrequently
diagnosed in women under 40 years of age. Because of late diagnosis, this disease
carries a high mortality rate of 7.9 per 100,000 women (14,500 deaths in the U.S. from
ovarian cancer in 1995) with a 5-year survival rate of approximately 30% (1).
Although epithelial ovarian cancer claims the lives of so many women, the
molecular events responsible for carcinogenesis have yet to be determined.
Epidemiologists have found associations between the development of ovarian cancer and
endocrine/reproductive, environmental, and genetic factors. One of the foremost of the
reproductive theories is that of “incessant ovulation” increasing risk of epithelial ovarian
cancer.
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This hypothesis that ovarian activity leads to neoplastic changes is based on the
premise that excess or inappropriate proliferation is a critical component in the early
pathogenesis of cancer in any system. During each ovulatory cycle, the surface
epithelium is ruptured and repaired, resulting in increased proliferation of the epithelial
cells. This elevated level of mitotic activity increases the likelihood of genetic mutations
that lead to malignant transformation (2).
This hypothesis is supported by numerous studies showing the protective effect of
parity, multiple births, history of breastfeeding, and oral contraceptive use - all of which
limit the number of ovulations. Compared to nulliparous women, those who were ever
pregnant have a 30-60% less risk of ovarian cancer (3). One to two pregnancies reduce
the relative risk even further to 0.49-0.97. Although trends involving months of
breastfeeding are lacking, some studies have shown a reduction in risk in those women
who breastfed compared to those who did not (4). Studies have consistently shown a
compelling ovarian cancer risk reduction of 30-60% in users of oral contraceptives (5).
In a World Health Organization study, women who had ever used oral contraceptives had
a relative risk of 0.75 (6). Other evidence in support of the “incessant ovulation” theory
are studies linking increased ovarian cancer rates with use of ovulation-inducing
infertility drugs (7).
In addition to a proposed role for ovulation in ovarian cancer, familial clusters of
ovarian cancer also suggest a genetic component. While the lifetime risk of a woman in
the general population developing ovarian cancer is 1.6%, this risk climbs to 4-5% if a
single family member is affected by ovarian cancer, and it increases to 7% if two
relatives are affected (8). Surprisingly, only 7% of all patients report a first-degree
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relative with ovarian cancer (9), demonstrating that the sporadic form of the disease is
much more common.
Three genotypes of hereditary ovarian cancer are recognized: breast-ovarian
cancer syndrome (linked to the susceptibility locus BRCA1 and BRCA2), ovarian cancer
only syndrome, and Lynch Type II syndrome which combines colorectal, endometrial,
and ovarian cancer (10). These are transmitted from either parent in the classic
Mendelian autosomal dominant pattern with incomplete penetrance and variable
prognosis. The predominant histologic type of hereditary ovarian cancer is serous
adenocarcinoma, and it is often diagnosed two decades earlier than those with sporadic
disease.
In addition to internal host factors, external factors from the environment may
also play a role in the development of epithelial ovarian carcinoma. Some have
speculated that dietary habits influence the risk of ovarian cancer. Animal fat and meat
intake have often been thought to increase the risk of many cancer types (11). In contrast,
Byers and others found no effect from fat intake on ovarian cancer risk (12). Other
proposed dietary risk factors include lactose-rich dairy products, coffee, and alcohol,
although there is no clear consensus regarding the effect of these products (13). Other
environmental risk factors have been investigated including talc exposure increasing risk
and mumps infection decreasing risk of ovarian cancer, but neither theory has been
proven.
Although epidemiologic studies have not offered clear answers regarding the risk
factors and precise etiology of ovarian cancer, scientists have extensively studied the
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pathologic changes occurring at the cellular level of the normal and neoplastic ovary in
order to address some of these questions.

V.A.2.

Histopathology of the Ovary and Ovarian Cancer
Although ovarian tumors arise from a single organ, they are not considered a

single entity. The pathologic details of ovarian cancers have been extensively examined
and classified into more descriptive categories.
In order to understand fully the pathologic variants of ovarian carcinoma, one
must first appreciate the histologic characteristics of the normal ovary. The human ovary
is a 3-5 centimeter ovoid shaped organ, comprised of stroma and follicles enveloped by
serosa. During embryonic development, the mesothelial lining of the coelomic cavity
gives rise to Mullerian ducts, from which the fallopian tubes, uterus, vagina, and ovarian
serosa are derived (10). The exterior of the ovary is covered by the tunica albuginea and
also by a single layer of cuboidal or columnar epithelial cells, which is continuous with
the mesothelium of the peritoneal cavity (14). As the ovary develops, the surface
epithelium extends into the stroma to form inclusion glands and cysts that are found as
early as the 12th week of fetal life (15).
In addition to fetal origin, inclusion cysts may be acquired throughout life.
During the postovulatory repair process, proliferating epithelial cells may be sequestered
as inclusion cysts where they are in turn eliminated by apoptosis. It is postulated that an
altered elimination process could result in the persistence within the stroma of these
entrapped epithelial cells (16). In this environment, the epithelial cells are exposed to
estrogen-rich follicular fluid and other proliferative stimuli, thus, leading to further
generation and propagation of mutations and potentially to carcinogenesis. In a study
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comparing the contralateral ovaries from patients with unilateral ovarian cancer to
ovaries of age-matched controls, there was an increase in the number of inclusion cysts
among the patients with ovarian cancer. Also, an age-related increase of inclusion cysts
was noticed in the study group, but not in the control group (17).
Assuming that the mitogenic microenvironment of an inclusion cyst does promote
gene mutations, it is important to identify exactly what mutations are responsible for
tumorigenesis. Considerable research has shown the p53 gene to be one such gene.
Alterations in this tumor suppressor gene are associated with negative cell cycle control,
as demonstrated in 50% of ovarian cancers (18). The erbB-2 (HER-2Ineu) oncogene also
plays an important role in ovarian cancer pathogenesis, but study results are inconsistent
in regards to the frequency with which this alteration is found among ovarian cancer
patients (18). Also found to be involved in tumor formation is the oncogene family ras,
which is one of the most frequently mutated genes in human malignancy (10). The K-ras
mutation occurs most often (26-75%) in the mucinous type of ovarian cancer. Also, the
myc gene family codes for a nuclear transcription factor that has been shown in four
small studies to be amplified in epithelial ovarian cancer (19). Another gene under
examination is fms, which encodes for M-CSF receptor. This receptor is produced by
ovarian cancer cell lines and is expressed by many ovarian cancers (20). Although many
genes have been implicated in ovarian carcinogenesis, there are many that remain
unidentified. In addition, the precise order and degree of accumulation necessary for
ovarian transformation has yet to be elucidated.
While the exact mutations responsible for ovarian cancer have not been identified,
it is certain that epithelial ovarian cancer accounts for 80-90% of all ovarian tumors and
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is responsible for the majority of ovarian cancer deaths (2). In the process of
carcinogenesis, the ovarian epithelium differentiates into cells resembling other
Mullerian-derived tissues. The most common subtype of common epithelial ovarian
cancer is termed serous (46%), similar to fallopian tube histology. Mucinous carcinoma
(36%) mimics the endocervix, while the endometroid type (8%) reflects endometrial
tissue. Finally, clear cell ovarian cancer (3%) is composed of glycogen-rich cells that
appear as endometrial glands would in pregnancy. Other less common classes include
transitional-cell tumors, mixed epithelial tumors, undifferentiated carcinoma, and
unclassified epithelial tumors (10).
Among the various categories of epithelial ovarian tumors, there is also a range of
behavior. Benign tumors, most commonly serous or mucinous in origin, are often large
and cystic. Ovarian neoplasms labeled “borderline” share an excellent prognosis, but
they also share histologic features suggestive of cancer. Fatalities from this type of
cancer are not usually seen until many years after the diagnosis. These women tend to be
older than the average benign case and younger than the average malignant case (21).
Malignant tumors are often discovered as solid masses with areas of necrosis and
hemorrhage. They can be distinguished from borderline tumors by destructive growth
features, such as disorganized cellular growth patterns, or sharp borders that transcend
stromal planes.
The natural history and patterns of ovarian cancer metastasis oftentimes follow a
predictable model of intraperitoneal or lymphatic spread. The transformation usually
takes place in the epithelium of the ovary, although 10% of cases arise as primary
peritoneal cancers. Upon further growth, the tumor ruptures the ovarian surface and
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enters the peritoneal cavity. From here, they may implant as surface nodules throughout
the peritoneum, especially on the omentum. The other mode of spread is through the
retroperitoneal lymphatics that drain the ovary, resulting in lymph node metastasis (10).
These patterns of spread are often appreciable at the time of diagnosis.

V.A.3.

Diagnosis of and Screening for Ovarian Cancer
At diagnosis, two-thirds of ovarian tumors are in advanced stages (beyond the

pelvis) because of late, non-specific signs and symptoms (2). In the early stages, women
may have irregular menses, or complaints due to pelvic mass effect including urinary
frequency, constipation, dyspareunia, and lower abdominal distention and discomfort.
Later symptoms such as increased abdominal girth, nausea, constipation, anorexia,
fatigue, and dyspnea may occur as a result of ascites, omental or small bowel metastases,
or pleural effusions (2).
If ovarian cancer is diagnosed early, a relative survival rate of 90% can be
achieved (22). However, there is a high fatality rate because the majority of women are
not diagnosed until they have advanced disease (23). Unfortunately, there is currently no
widespread, reliable screening modality for the early detection of ovarian cancer.
The screening tests available are bimanual rectovaginal pelvic examination, CA125 testing, and ultrasonography (10). The most common of these tests, the annual
physical examination, has not been shown to be adequate for detection in that it has
insufficient sensitivity and specificity (23).
Although transabdominal ultrasound was once thought to be a promising
noninvasive technique of ovarian cancer detection, it has since proven to be inadequately
specific. In an abdominal ultrasound study of 5479 women, 338 had positive screens
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followed by laparotomies. Of those, only 5 were found to have Stage I ovarian cancer
(24). Researchers have placed new hope on transvaginal ultrasound, which is purported
to be a more specific test. In one study of TVS, the PPV was reported as 6.7% (25) - that
is 15 laparotomies for every one cancer. The most recent advancement in this area is the
addition of color flow Doppler to reduce the high rate of false positives. This would
distinguish malignancies from benign disease or from normal ovaries by analyzing the
neovascularization and pulsatility of a mass (10).
Finally, the cell surface glycoprotein CA-125 has been used as a serum tumor
marker. The normal physiologic function of CA-125 is unknown, but in healthy adults, it
is found on the fallopian tube lining, endometrium, endocervix, peritoneum, pleura,
pericardium, and bronchus (26). Very little CA-125 can be detected in the normal ovary,
although it is sometimes found in inclusion cysts. It is elevated in 80-90% of all patients
with epithelial ovarian cancer and in one-half of women with Stage I and Stage II ovarian
cancer. Levels are also increased in patients with benign conditions such as peritonitis,
pancreatitis, renal failure, and alcoholic hepatitis (27). The high false-positive rate
combined with the low incidence of epithelial ovarian cancer makes a single CA-125
assay ineffectual (10).
Other antibody serum markers with different antigenic determinants for ovarian
cancer are under investigation in hopes of improving the sensitivity and specificity.
Some of these include ovarian carcinoma-associated antigen (OCA) and macrophage
colony stimulating factor (M-CSF).
While each of these screening tests alone cannot offer adequate specificity or
PPV, some researchers have looked at a combination of the methods. In a study of
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22,000 women without a family history of disease, CA-125 levels were determined first.
Only if there were an elevation did the patient receive a transabdominal ultrasound. The
overall PPV increased to 26.8% when modalities were combined. Although
improvement was seen with the multi-modality approach, the PPV for detection of early
stage disease remained below 10% (28).
The National Institutes of Health Consensus Conference on Ovarian Cancer
determined based on the above findings that there was “no evidence available yet that the
current screening modalities of CA-125 and transvaginal ultrasonography can be
effectively used for widespread screening to reduce mortality from ovarian cancer nor
that their use will result in decreased rather than increased morbidity and mortality” (23).
Therefore, there are currently no ovarian cancer screening recommendations.
Because there are no widespread screening programs for ovarian cancer, patients
are often diagnosed with advanced disease, requiring exhaustive treatment plans.

V.A. 4.

Treatment of Ovarian Cancer
Once ovarian cancer is diagnosed, there are several treatment options -

cytoreductive surgery, chemotherapy, and radiation therapy - but the precise sequence
and complex combination of therapies is determined by the surgical stage of disease.
Therefore, the first step in surgical management is to stage the disease (see next
section). The next goal is to remove any large or visibly metastatic disease in order to
facilitate diffusion of cytotoxic agents into the tumor, to limit the number of resistant
clones, to remove any slow-growing masses that would not respond to chemotherapy, and
to improve discomfort in the patient (2). A tumor that is amenable to optimum debulking
has been shown to carry a better prognosis (29).
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The chemotherapeutic regimen has undergone many changes over the last few
decades. Before the late 1970’s when both combination chemotherapy and cisplatin were
introduced, patients were treated with single agents such as melphalan. Cisplatin
combination therapy (with doxorubicin and cyclophosphamide) quickly became the
regimen of choice. Currently, carboplatin has become the preferred platinum compound
due to fewer ototoxic, neurotoxic, and nephrotoxic effects than cisplatin. In 1996, the
utility of cisplatin/paclitaxel combination therapy was demonstrated in patients with suboptimally debulked Stage III and IV tumors (30). Another study found a survival
advantage in certain patients who received cisplatin via an intraperitoneal route rather
than intravenous administration (31). Newer drugs under investigation include docetaxel
(a member of the taxane family), gemcitabine (a pyrimidine antimetabolite), topotecan (a
topoisomerase-1 inhibitor), buthionine-sulfoximine (an inhibitor of glutathione
biosynthesis), and cyclosporin (an antiinflammatory that that increases cisplatin toxicity)
(32).
The use of radiotherapy in the treatment of ovarian cancer is a controversial
topic due to early trials involving inappropriate techniques, doses, and patients. In the
past decade, advancements have been made in the strategy of radiation therapy. For
example, the knowledge of intraperitoneal dissemination led to techniques involving
radiation of the entire peritoneal cavity rather than the pelvis alone. The ideal patient has
also been better characterized as one with no macroscopic residual disease after primary
surgery (10). Long-term, relapse-free survivals have been reported for Stages II and III
after optimal debulking and postoperative radiotherapy (23). This modality of
management continues to be debated although supportive data exists.
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Despite these advances in ovarian cancer therapy, the prognosis remains dismal.

V.A.5.

Ovarian Cancer Prognosis
The most important factor in determination of epithelial ovarian cancer prognosis

is the tumor stage. Therefore, careful staging of ovarian cancer is of critical importance.
The stage, or the extent of disease at the time of diagnosis, is determined by exploratory
laparotomy for ovarian cancer. The general procedure is as follows: vertical rather than
low transverse incision is made; multiple cytologic washings are performed; the tumor is
removed intact; the abdomen is completely explored; the remaining ovaries, uterus, and
tubes are removed; the omentum is removed, lymph nodes are sampled, and random
peritoneal sites are biopsied. The results of this comprehensive surgery will decide the
anatomic stage of disease and will direct all postoperative therapy and prognosis, so the
skill and experience of the surgeon is of critical importance (10).
When studies evaluated the frequently inadequate surgical staging of early
ovarian cancer and corrected for the apparent understaging of patients, the 5-year
survivals improved. Stage I disease, previously reported to have a 60-80% survival was
more accurately shown to reach 5-year survivals of 90% (22). Similarly, Stage II disease,
originally reported as 0-40% survival had rates as high as 80%. Stage III and IV disease
was not misstaged as often and therefore the survivals remained at 15-20% and 5%,
respectively (33).
There is a myriad of other factors contributing to the prognosis of ovarian cancer.
The diminished volume of residual disease after an optimal cytoreductive can improve
patient survival by 22 months as compared to a patient with sub-optimal debulking (10).
Histologic grade is another predictor of survival, especially in patients with Stage I

disease. Although the preoperative CA-125 level is often obtained, it only reflects the
volume of disease, and it is not as predictive of survival as the postoperative levels (34).
Some physicians feel that the CA-125 concentration after 2-3 courses of chemotherapy is
the most important predictor of survival (35), while others believe that CA-125 levels
should not be used for treatment decisions in individual patients (36).
Some investigational approaches to ovarian cancer prognosis are being explored.
Among these are platinum-DNA adduct levels as a sign of responsiveness to
chemotherapy, epidermal growth factor receptor and gene levels as a risk factor of
progression, elevated p53 levels as an association with an unfavorable prognosis, and
ploidy analysis as a marker of differentiation.
While the epidemiology, histopathology, diagnosis/screening, treatment, and
prognosis of ovarian cancer differs from that of most other tumors, the fundamental
defect underlying all cancers appears to be the same - resistance to apoptosis. This
represents the main focus of the present study. Specifically we evaluate the role of the
Fas/FasL system (a main apoptotic pathway) in the regulation of programmed cell death
in normal ovarian tissue as well as during neoplastic transformation..

V.B.

V.B. 1.

Programmed Cell Death and the Ovary

Fas/ FasL and the Immune System
The Fas and Fas ligand (FasL) system plays a dual role - protector and assassin -

in the regulation of cellular proliferation and cell death in tissues. However, it is only
recently that researchers have begun to study and understand the relevance of these actors
(37).
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Fas (Apo-l/CD95) is a type I cell surface protein responsible for the initiation of
events leading to apoptosis when ligated by its natural ligand (38). The Fas receptor
shares homology with members of the tumor necrosis factor (TNF)/ nerve growth factor
(NGF) receptor family, and it is widely expressed in a variety of cells in the immune
system, including T cells, B cells, and monocytes (37). In addition, the Fas receptor can
be found throughout the body in such tissues as the liver, heart, and kidney (39).
FasL, the natural ligand for the Fas receptor, is a type II membrane protein
belonging to the TNF superfamily. It is predominantly expressed in activated T cells and
activated NK cells, but is also found on some macrophages/monocytes, and on the cells
of immune privileged tissues (37).
Apoptosis is a pattern of programmed cell death responsible for many physiologic
and pathologic events including: embryogenesis, following hormone dependent
involution (endometrial cell shedding, regression of the lactating breast), cell death in
proliferating cell populations (intestinal crypt epithelia), tumor cell death, immune cell
death, pathologic atrophy, and cell death due to cytotoxic T cells or certain viruses'
infection (40). The Fas/FasL system plays an important role in many of these processes.
During apoptosis, cells undergo a specific sequence of morphologic events. The
first step is cell shrinkage, followed by chromatin condensation, formation of apoptotic
bodies (blebs), and finally phagocytosis of apoptotic bodies or cells (41). This process,
unlike necrosis, does not elicit inflammation. This allows for elimination of a cell
without destruction of its surrounding tissue.
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The mechanism of apoptosis in the Fas/FasL system involves a cascade of
proteases triggered by the binding of Fas ligand with and the subsequent trimerization of
the Fas receptor (Fig. 1).
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Figure 1. Model of internal events
_in apoptotic cell._

that of immune system
It is well known that cytotoxic

T cells act by inducing target cells to undergo apoptosis (44). The principal mechanism
by which T cells mediate cell death is via cytotoxic proteins, which they release upon
recognition of the target cell. These proteins include perforins, granzymes (fragmentins),
and lymphotoxins. In addition to granule-mediated killing, membrane proteins of CD8 T
cells can also activate apoptosis. This mechanism is believed to involve the activation of
Fas in the target cell membrane, which interacts with FasL on the cytotoxic T cell
membrane, resulting in cell death (44).
More recently, the Fas/FasL system has been shown to be involved in peripheral
tolerance in the immune system. During maturation, T cells recognizing self-peptides are
usually deleted in the thymus before they can migrate to the periphery (44). Once they
have migrated to peripheral tissues, T cells responding to a strong antigenic stimulus
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(such as self-peptides) decrease in number over time. Chronic activation of T cells leads
to proliferation and expression of both Fas and FasL, resulting in apoptotic death of the T
cells (45) thereby preventing destruction of tissue.
Finally, in the process of activation-induced cell death (AICD), the Fas/FasL
system appears to regulate the expansion of lymphocytes by acting in an autocrine
fashion to delete recently activated T cells (42). This T cell suicide enables the immune
system to mount an attack without continually expanding the immune response at the site
of infection. In patients with mutations in the Fas receptor, this expansion is unregulated,
and they develop disfiguring lymphadenopathy due to an autoimmune
lymphoproliferative syndrome (46).
In addition to playing a crucial role in immune system maintenance, Fas/FasL has
also been shown to regulate apoptosis in other systems of the body and even serve to
protect certain organs from immune system attack.

V.B.2.

Fas/FasL and Immune Privilege
The role of the Fas/FasL system in the regulation of cellular homeostasis is not

confined to the immune system. This system also allows for certain sites and tissues in
the body to evade immune system attack and therefore to be immunologically privileged.
Privileged sites are those regions in the body that offer special protection to grafts,
by preventing immune reactions and graft rejection in response to histocompatibility
differences. Such locations include the brain, anterior chamber of the eye, cornea, retina,
cartilage, matrix of hair follicles, testis, ovary, prostate, mammary and subcutaneous fat
pads, and pregnant uterus, (47). From the evolutionary standpoint, preventing an
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inflammatory response in these specialized tissues is beneficial as such responses in these
sites could have fatal consequences for the individual organism or for the species.
It was once thought that this privileged status was due to separation of the
antigens and the immune system. Some believed that physical barriers caused
sequestration of the antigens from T cells. For example, some of these sites possess a
blood-tissue barrier, making it difficult for immune cells to penetrate (47). Also, most of
these sites lack conventional lymphatic drainage (47). Others believed that the antigens
failed to leave these sites in order to elicit an immune response. However, studies have
shown that antigens do in fact leave and do interact with T cells (44).
Current theories are more complex, focusing less on mechanical barriers and more
on active mechanisms of immune evasion. Some of these theories include reduced
expression of classical MHC glycoproteins (48) or the local secretion of
immunosuppressive cytokines and neuropeptides (38). One hypothesis involves the
preferential stimulation of the anti-inflammatory TH2 cell response as opposed to the
inflammatory responses of TH1 cells and complement-fixing antibodies (47).
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Recently, an additional mechanism of immune privilege was realized after
researchers determined that both the eye and the testis constitutively express FasL (Fig.
2) (38). After inoculation with virus, the anterior chamber of the eye incurs no
inflammatory injury, because the FasL on the epithelial surfaces induce apoptosis of the
invading lymphocytes. This is not the case in gld mutants, mice with defective FasL.
Instead, the recruited lymphocytes are not killed, the inflammatory response is
uncontrolled, and the eye tissue is destroyed (45).
In a study by Bellgrau et al., this same protective effect was seen in the context of
the testicle. This group transplanted allogenic mice testes into the kidney capsules of
recipient mice. The graft was successful if both Fas and FasL were functional. If,
however, the donor lacked functional FasL {gld mouse) or the recipient expressed
defective Fas {Ipr mouse), the graft was vigorously rejected (49).
The Fas/FasL system has also been shown to be involved in immune regulation at
the site of placental implantation. Mor et al. localized FasL to the matemal-trophoblast
interface and identified apoptotic leukocytes at this junction (50), suggesting that FasL
triggers programmed cell death in immune cells which affords the placenta an immune
privileged state.
While FasL provides immune protection to certain organs, its interaction with Fas
accounts for the normal cellular turnover inherent to tissues undergoing continual
proliferation and cell death. It is in this capacity that the Fas/FasL system acts in the
development of normal tissues.
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V.B.3.

Fas/FasL in Norma! Reproductive Tissue
As previously mentioned, the process of apoptosis is responsible for normal

cellular turnover in numerous tissues throughout the body. The cyclic nature of the
female reproductive system, imposed on these tissues by the episodic release of ovarian
steroids, is particularly dependent on this means of cell death. The variable coexpression
of Fas and FasL is believed to be in part responsible for the proliferative/degradative
changes occurring in these tissues.
The uterus shows prominent steroid-dependent cyclic changes in structure and
function in preparation for pregnancy. After a proliferative and secretory phase, steroid
support is withdrawn and the uterine epithelium is shed. While menstruation was once
thought to be the result of ischemic necrosis, Hopwood and Levision later demonstrated
the presence of apoptosis in the human endometrium (51). Fas and FasL have been
reported to be consistently co-expressed in the human endometrium throughout the
menstrual cycle (52). During the late proliferative phase, these proteins are primarily
located on the Golgi apparatuses and vesicles, and therefore are unable to interact and
cause apoptosis. In contrast, the

OVULATION

proteins are incorporated into the
cellular membranes during the
secretory phase when F asL can
bind Fas and signal apoptosis. In
addition, on Western Blot analysis,
it was demonstrated that FasL
Figure 3.

Model of cyclic changes in female reproductive tissues.

exhibits a cyclic expression pattern
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in the endometrium with a peak during the secretory phase (Fig. 3) (52).
The hormonally regulated, dynamic tissue of the breast also undergoes cyclic
reorganization. During pregnancy, the glandular epithelium experiences a cycle of
lobulo-alveolar development and maturation in preparation for milk production, followed
by mammary involution after cessation of lactation. Studies involving the pregnant and
postpartum breast indicate a role for apoptosis during the involution of mammary gland
tissue. Quarrie et al. demonstrated the presence of apoptotic cells in mouse mammary
tissue by the technique of nick-end DNA labeling. They found laddering both before and
then increasingly after litter removal, suggesting that while apoptosis is a normal
physiological event in the lactating mammary gland, it is also rapidly induced by milk
stasis (53). Furthermore, this apoptotic event in the mammary gland has been divided
into two distinct phases. The first phase is characterized by apoptosis of fully
differentiated mammary epithelial cells without visible degradation of the extracellular
matrix. The last phase involves remodeling of the extracellular matrix, altered
mesenchymal-epithelial interactions, and apoptosis of cells that are losing differentiated
functions (54).
Recently, Song and others have linked this pattern of apoptosis in the pregnant
breast to the changing expression of Fas and FasL in the mammary epithelium. They
have shown the absence of FasL in the breast tissue of non-pregnant/virgin mice,
followed by the increasing appearance of FasL expression during pregnancy and
lactation. Corresponding to this rise in FasL, Fas expression is diminished, allowing for
growth of mammary tissue without induction of apoptosis. Once the puppies are weaned,
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high levels of both Fas and FasL are observed in the maternal breast, which coincides
with the emergence of apoptotic cells in the ducts and glands (Song:submitted to PNAS).
Similarly, the Fas/FasL system may play a prominent role in the ovary by
mediating cellular turnover, as exemplified by follicular atresia and by post-ovulatory
surface epithelial repair. The ovarian cycle consists of follicular and luteal phases (Fig.
3). As estrogens are derived from the follicles, the estrogen-dominant period prior to
ovulation is known as the follicular phase while the progesterone-dominant phase is
termed the luteal phase as the corpus luteum, the postovulatory remnant, secretes an
abundance of progesterone. It is the ovarian secretion of estrogen and progesterone that
coordinates the cyclic activities of the genital tract and breast with the ovulatory cycle.
During the follicular phase, 15-20 early antral follicles are rescued from atresia and
recruited for development at the start of each menstrual cycle. Of these 15-20 early antral
follicles, there is usually only one successful follicle that will undergo subsequent
preovulatory growth. It is this single follicle that develops LH receptors on its granulosa
layer and is therefore able to ovulate in response to the LH surge. Meanwhile, the
majority of the follicles are eliminated by the process of atresia in order to maintain the
cell mass and homeostasis of the ovary.
The method by which follicles degenerate had long remained a mystery, until
recent reports identified apoptosis as the underlying mechanism of follicular selection
(55). Previous studies have shown the following physiological markers associated with
follicular atresia: detachment and degeneration of the granulosa layer (56), fragmentation
of the basal lamina (57), reduced DNA synthesis (58), decreased estrogen production
(59), and decreased gonadotropin binding (60). Recent evidence demonstrates that the

20

intemucleosomal fragmentation of DNA that is characteristic of cells undergoing
apoptosis can be detected in ovarian atretic follicles (55). Atresia is therefore achieved
by the self-destruction of thecal and granulosa cells that comprise the follicle, by this
process of apoptosis.
Upon realizing that follicular regression was dependent on apoptosis, many
researchers began searching for the underlying mechanism of apoptotic regulation in the
ovary. The Fas/FasL system has been implicated in such a role. Guo et al. found the
expression of both Fas and FasL in the murine ovarian follicle. They localized Fas to the
oocytes (61) while FasL appeared to be restricted to the area of the granulosa cells by
indirect immunofluorescence (IIF) test. In addition, FasL expression was regulated by
the administration of pregnant mare’s serum gonadotropin (PMSG) (61). Hakuno et al.
also detected Fas in the ovary, but they localized this protein to granulosa cells in
secondary and tertiary follicles at an early stage of atresia through immunohistochemical
and in situ hybridization analyses. Furthermore, on Western Blot analysis of the oocytes’
lysate, they identified a 31- kDa band specific for FasL (62). In another study of the rat
ovary. Fas and FasL were found to be coexpressed in granulosa cells (63). In an attempt
to localize the Fas antigen in the infant and adult human ovary, Kondo et al. found
moderate Fas expression in the oocytes of primordial and primary oocytes. This
expression was only weak in the oocytes of secondary and antral follicles, and there was
a complete absence of staining in preovulatory follicles. In addition, they detected an
abundance of Fas antigen in the regressing corpora lutea, suggesting Fas/FasL
participation in this aspect of the ovulatory cycle as well (64).

21

Another cyclic pattern of apoptosis in the ovary occurs in the ovarian surface
epithelium (OSE). At the time of ovulation, these cells on the surface of the preovulatory
follicle undergo apoptosis. Once the follicle has ruptured, this layer of cells rapidly
proliferates in order to repair and cover the surface of the developing corpus luteum (65).
Researchers studied the effect of adding Fas monoclonal antibody to mouse corpus
luteum cultures and to enriched cultures of mouse OSE to determine the role of Fas/FasL
in this apoptotic event. They concluded that OSE cells were triggered to undergo
apoptosis in response to Fas mAb when they were pretreated with IFN (66) and,
therefore, Fas/FasL likely plays a role in the apoptosis of ovulation.
If a problem arises in this normal cellular removal process, it may enable certain
cells to proliferate without control, potentially resulting in a transformational event.
Theoretically, these cells would then be recognized as abnormal or “foreign” by a
functional immune system and promptly eliminated. In fact, many components of the
immune system do identify these pre-neoplastic cells and do attempt to clear them from
the body.

V.C. Fas/FasL in the Normal and Neoplastic Ovary - A Role
for Tumor Escape
V.C.l.

The Immunology of Ovarian Cancer
Basic research in the field of immunology has revolutionized our understanding

of the cellular and molecular basis of immunity and the principles of tumor immunology.
It is now known that tumors have chemically defined antigens on their surface that differ
in quality and quantity from those on normal host cells (10). Some of these tumorassociated antigens are recognized by the host’s immune system, and treated in a similar
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manner as an infection. The traditional components of the immune system - various
leukocytes, cytokines, complement cascades, and MHC antigens - all play a significant
role in stimulating and regulating this immune response to cancer.
Just as leukocytes perform an integral role in defending the body from infection,
T and B lymphocytes, macrophages and monocytes, and natural killer cells all cooperate
to combat tumors. T cells are the primary effectors of cell-mediated immunity with
offspring that both regulate other leukocytes through cytokines and become cytotoxic
cells capable of lysing malignant cells. Both CD4+ and CD8+ T cells have been
observed in ovarian carcinomas (26). T lymphocytes from ovarian cancer patients have
been shown to inhibit allogeneic tumor cells of the same tissue type (68); however, the
overall number of T cells seems to be slightly decreased in this disease (69).
The B cells of the humoral immune system may also help attack cancer by
production of antibodies that bind to specific tumor antigens, leading to inactivation,
uptake, digestion, and elimination of these antigens (10). Antibodies against tumor cells
have been detected in the sera and ascites of patients with ovarian cancer, but have not
been shown to mediate tumor resistance (70).
Macrophages appear to have both a beneficial and harmful effect in their response
to tumors. Activated macrophages can distinguish transformed from benign cells by
recognizing alterations in the cell membrane, and then they destroy tumor cells through
direct ingestion (71). In addition to phagocytosis of cancer cells, macrophages also
produce cytokines. Unfortunately, these cytokines (IL-1, IL-6, and TNF-a) have been
shown in vitro to stimulate the growth of ovarian carcinoma cell lines (72). Furthermore,
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most ovarian cancers produce M-CSF, attracting circulating monocytes and activating
macrophages (73).
Natural killer cells can also control the growth of tumors. These cells can mediate
the death of neoplastic cells without antibody or specific immunity. The NK cell can do
so without having previous contact with the target cell (10).
Although many human cells are resistant to complement-mediated killing, the
binding of antibodies to certain tumor-associated antigens can trigger the cascade and
result in membrane attack complex insertion and impaired osmotic integrity. This
method of defense also activates neutrophils, basophils, and mast cells to create an
inflammatory response (10).
In addition to mediating graft rejection after tissue transplantation, MHC
molecules also trigger an immune response to most antigens recognized by T cells. An
individual’s MHC complex is able to bind particular peptides and to recognize a tumor
cell. Fragments of antigens synthesized within a tumor cell may become associated with
Class I MHC antigens on a tumor cell surface, making an effective target for cytotoxic T
cells. Also, inducer T cells can be stimulated by tumor peptides bound to Class II MHC
antigens (10). Although it has not been correlated with survival (74), it is interesting to
note that about 80% of both normal ovary and epithelial ovarian carcinomas express
Class I MHC determinants, while only 40% of ovarian cancers and no normal ovaries
express Class II antigens (26).
Despite the many attempts of an active immune response, the ovarian tumor is
often able to “escape” the immune system. This process of evasion has been suggested to
result from the inability of the immune system to react to the tumor either because of
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non-recognition of these antigens or due to non-reactivity secondary to insufficient co¬
stimulation, anergy, tolerance, or immunosuppression. Recently, the expression of FasL
in neoplastic cells has been suggested as a potential mechanism of tumor immune
privilege.

V.C.2.

FasL in Cancer
Although the immune system is often capable of identifying and attacking

transformed cells, some cancers have discovered a successful means of retaliation - FasL
expression. This model postulates that lymphocytes, constitutively expressing Fas,
recognize and infiltrate a neoplasm, encounter the FasL expressing tumor cells, and
undergo death via apoptosis signaled by the Fas-FasL interaction (45).
Numerous tumors have been reported to express FasL, including hepatocellular
carcinoma, melanoma, colon cancer, astrocytoma, and lung carcinoma (42).
Furthermore, these tumor cells were shown to induce apoptosis in Fas-sensitive but not in
Fas-resistant Jurkat lymphocyte cell lines (75). In addition to these sites, a variety of
reproductive tissue tumors escape immune surveillance via FasL expression.
In an extension of their work on FasL and placental implantation, Mor et al.
investigated the role of FasL expression in the context of gestational trophoblastic disease
and immune evasion. They assert that the same mechanism by which the placental
trophoblast cells subvert the maternal immune system during implantation is utilized by
neoplastic choriocarcinoma cells during uterine invasion. Using immunohistochemistry
and reverse transcriptase-polymerase chain reaction, a high expression of FasL was found
in both complete hydatidiform moles and in choriocarcinoma. In the vicinity of these
invading tumor cells were apoptotic leukocytes, suggesting that FasL acts as an effector
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signal to kill activated lymphocytes, thereby offering escape from the host’s immune
system (50).
A similar mechanism of uncontrolled growth and invasion has been proposed for
breast carcinoma. Breast tumors are often associated with a large, seemingly ineffective
lymphocytic infiltrate that is unable to suppress or eliminate the “foreign” cells to which
it is directed. This immune incompetence may be a result of lymphocyte apoptosis
induced by the Fas/FasL system. In a study of human breast carcinomas, Gutierrez et al.
found strong membranous and cytoplasmic FasL staining in ductal carcinomas and in
hyperplastic breast tissue while there was no staining in normal glands in non-tumor
quadrants. As in the choriocarcinoma study, TUNEL analyses and CD3+ staining
demonstrated apoptosis predominantly among the lymphocytic population. There also
appeared to be an up-regulation of FasL expression in hyperplastic and normal breast
ducts close to the tumor, suggesting a possible role in early neoplastic transformation and
proliferation (76).
Currently, the literature on the relationship between Fas/FasL and ovarian
carcinoma is sparse. One group obtained lymphocytes from ascitic fluid of women with
ovarian cancer and showed an alteration in T cell receptor function related to tumorinduced apoptosis (77). Other groups have focused on the treatment of ovarian cancer by
administering anti-Fas mAb (FasL) to induce apoptosis of Fas-bearing cell lines (16,78).
Overall, this is a research area lacking in clear answers regarding the role of FasL in the
transformation and growth of ovarian cancer.
We propose that FasL overexpression could result in escape of tumor cells
from immune surveillance. Furthermore, this abnormal expression of FasL may
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represent a precursor stage of ovarian epithelial carcinoma. In this study, we investigate
the expression of FasL in the carcinogenesis of ovarian epithelial cancer.

V.D.

Hormonal Regulation of FasL

V.D.L

Effect of Estrogen on FasL
Several hormones are involved in human reproductive activity, among those

being the steroid hormones. Included in this class are progestagens, androgens, and
estrogens, all of which are derived from the common sterol precursor cholesterol. While
the three classes of sex hormones share a common biosynthetic pathway and even have
similar basic structures, the functional properties of each class are vastly different (79).
In general, the progestagens are associated with preparations for pregnancy and its
maintenance, the androgens are responsible for the development of masculine
characteristics and fertility, and the estrogens promote development and maintenance of
female qualities and fertility. Specifically, estrogens stimulate female secondary sex
characteristics, prepare the uterus for spermatozoa! transport, increase vascular
permeability and tissue edema, stimulate growth and activity of mammary glands and
endometrial tissue, prepare the endometrium for progestagen action, stimulate
calcification, regulate secretion of gonadotropins, and support pregnancy (80).
The ovary is the main source of estrogen, synthesized in granulosa cells from
androgenic precursors of the theca (80). Estrogen regulates tissue function by
modulating gene transcription (Fig. 4) (81). The hormone-activated estrogen receptor
binds to specific estrogen-recognizing elements (ERE) located in the promoter region of
estrogen-regulated genes. Mor et al. reported the presence of ERE-like motifs
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(AGTCANNNTGACC) in the promoter region of the human FasL gene at nucleotides
543-552 (82). This finding suggested that estrogen could have a direct effect on FasL
expression. Further studies confirmed this hypothesis. MCF-7 breast cancer cells treated
with 17-|5~estradiol (1x10"9M) induced a three-fold increase in FasL expression at both
the mRNA and protein levels after 24 and 48 hours of incubation (82). In addition to

estrogen influencing the expression of FasL in the breast, its antagonist, tamoxifen, has
also been implicated in such a regulatory role.

V.D.2.

Effect of Tamoxifen on FasL
Antiestrogens block the action of estrogen usually by binding to receptors and

interfering with their normal function. These antagonists are traditionally divided into
three groups: short-acting antagonists (estriol), long-acting antagonists (tamoxifen,
clomiphene), and physiological antagonists (progesterone, androgens, glucocorticoids).
Of most current clinical relevance are the long-acting antagonists, such as
tamoxifen, which are derived from triphenylethylene. They have both agonist and
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antagonist effects on estrogen action (83). As a mixed agonist-antagonist, tamoxifen
partially inhibits the action of estrogen but partially mimics the response of estrogen.
The species, organ, tissue, or cell type ultimately determines the overall effect. For
example, when administered alone, tamoxifen stimulates growth of the rat uterus by
causing hypertrophy of the epithelial cells in the endometrium while having little effect
on the stroma or myometrium. Unlike tamoxifen, estradiol stimulates growth of all three
tissue layers. If tamoxifen is given simultaneously with estradiol, it will inhibit the
overall estrogenic growth effect through antagonism in the stromal and myometrial
compartments although it is an agonist in the epithelial layer (84).
The mechanisms underlying this tissue-selective action of mixed agonistantagonists are not fully understood. The physiochemical characteristics of antiestrogenreceptor and estradiol receptor complexes may differ and thereby undergo contrasting
conformational changes (85). Tamoxifen induces an intermediate conformation,
balancing between active and inactive states. The final result depends on the intracellular
concentration of coactivators and corepressors, providing a potential means of differential
cell stimulation (86).
Antiestrogens have been used in the management and now in the prevention of
breast cancer. The main indication for their use arises from the observation that estrogen
is a mitogen in mammary carcinoma (82). Tamoxifen appears to have an antiestrogen
effect in human breast tissue, inducing a therapeutic response in about one third of
women and men with breast cancer (87). Alternatively, chronic tamoxifen use is
associated with an increased risk of endometrial cancer, owing to its agonistic effect in
the epithelial cells of the uterus (88).
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In addition to demonstrating that estrogen up-regulates FasL expression in breast
tissue, Mor et al. also found that tamoxifen inhibits FasL expression, thereby preventing
tumor escape from immune surveillance. When co-administered with estrogen,
tamoxifen inhibited the stimulatory effect of estrogen. This supported the idea that
estrogen’s action on FasL expression is receptor-mediated. When MCF-7cells were
incubated with increasing concentrations of tamoxifen alone, there was a dose-dependent
down-regulation of FasL mRNA expression (82). To confirm that the effect of tamoxifen
on FasL is estrogen receptor-dependent, similar experiments were performed on the Jar
choriocarcinoma cell line that is negative for both a and

estrogen receptors. Tamoxifen

did not have any effect on the expression of FasL under these circumstances.
In contrast to breast cancer, ovarian cancer appears to be hormone-unresponsive.
Although 40-60% of ovarian cancers express ER-a (89), only 7-18% of these clinically
respond to antiestrogen treatment (90), although it does seem effective in disease
stabilization. Schwartz et al. used tamoxifen to treat 13 patients with recurrent ovarian
epithelial cancer and had no complete responses, one patient with a partial response, and
four patients with prolonged stabilization of disease (91). While preliminary results of
hormonal therapy in ovarian cancer seem unsuccessful, further studies are necessary in
order to confirm this.
We hypothesize that similar to the breast, the expression of FasL in the ovary
may also be regulated by estrogen and tamoxifen. Because both estrogen and
tamoxifen affect cells by binding to their intracellular estrogen receptors, investigation
into these receptors could help explain the variable responses of different tissues to these
hormones.
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V.E.

V.E.L

ER alpha and beta Expression in the Ovary

Estrogen Receptors
Estrogen receptors are members of the nuclear steroid receptor superfamily and

act as transcriptional factors, targeting organs such as bone, brain, and reproductive tissue
(92). The classic ER-a was thought to be the only receptor to which estrogen could bind,
until 1996 when researchers cloned a novel estrogen receptor, ER-p, expressed in rat
prostate and ovary (93). In addition, other estrogen target tissues have been shown to
coexpress ER-a and the second
isoform ER-f3 (Fig. 5), including
breast, endometrium, and testis (94).
The ERa is translated from a 6.8kilobase mRNA that contains 8 exons
derived from a gene on the long arm of chromsome 6 and has a molecular weight of
about 66,000 with 595 amino acids. The more recently discovered ER^ is encoded by a
gene localized to chromosome 14q22-q24, close to genes related to Alzheimer’s disease
(95), and encoding some nine to 10 differently sized ERp isoforms in the range of 485,
503 and 530 amino acids (95, 96). The affinity for the 17j3-estradiol and other known
estrogen receptor ligands was found to vary between the ERa and the different ER(3
isoforms (97). Although, they respond in a comparable manner to the same hormones,
there are differences. For example, phytoestrogens have a greater affinity for ER(3 than
ERa (98). Whether all the ER(3 isoforms will turn out to have any significant biological
and physiological role is yet undetermined. This recent characterization of ER~f3
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provides a new means for understanding the pathophysiology of estrogen-regulated
tissues.

V.E.2.

ER Expression in Cancer
For many years, ER-a expression in breast cancer has been correlated with tumor

progression, prognosis, and the prediction of hormone sensitivity (99); however, the
significance of ER-a and ER-P in ovarian cancer has only recently been appreciated. In
the normal human ovary, both ER isoforms are present. Hillier et al. showed that both
ER-a and ER-p PCR products were weakly detectable by Southern analysis in cultured
human ovarian surface epithelial (OSE) cells and readily detectable in freshly isolated
granulosa cells and granulosa-lutein cells (100). In another study of normal ovary ER
expression, Lau et al. found coexpression of ER-a and ER-p in four primary cultures of
human OSE cells (101). Brandenberger et al. also demonstrated the expression of both
estrogen receptors in normal, pre-, peri-, and postmenopausal ovaries at comparable
levels in all age groups. In contrast, human fetal ovary predominantly expressed ER-p
mRNA. In analysis of specific cell types, however, they found that the human OSE cell
line IOSE-Van expressed a low level of ER-a and no ER-p and that granulosa cells
expressed high levels of ER~p (102).
Further estrogen receptor studies of the ovary indicate a role for differential ER-a
and ER-p expression in ovarian carcinogenesis. Brandenberger et al. found that ER-a
mRNA levels were equal or slightly higher in carcinomas of the ovary while there was a
decrease in the level of ER-p in the tumor samples (102). Pujol et al. also analyzed the
relative expression of ER-a and ER-P in malignant human ovarian epithelial tumors.
They reported a similar finding - an increased level of expression of ER-a mRNA in
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comparison to ER-|3 mRNA in ovarian cancers. Furthermore, their study showed a
difference in estrogen receptors between cysts and tumors (103). Thus, the increased ERa:ER-p ratio may represent an early step in carcinogenesis and a potential marker of
aggressiveness.
To evaluate the potential role of ER in ovarian cancer, we analyzed the relative
expression of ERa and ER|3 mRNA and protein in normal ovarian tissue and primary and
metastatic tumors.

V.F.

Rationale
Our lab and others have identified FasL as a key mediator of tumor immune

escape by induction of apoptosis in invading T cells. In particular, this phenomenon has
been demonstrated in such tumors as breast cancer and gestational trophoblastic disease
(50,76). While the Fas/FasL system has been shown to underlie apoptosis in follicular
atresia, it is unclear if FasL is also the mechanism by which ovarian cancer escapes
immune surveillance.
It is known that hormones influence growth of normal and neoplastic reproductive
tissues including breast, uterus, and ovary, and we have even shown that FasL expression
in breast tissue is responsive to estrogen stimulation (82). However, this same regulation
of FasL by estrogen has yet to be demonstrated in the ovary.
Estrogen is known to assert its effect via two estrogen receptor subtypes, ER
alpha and ER beta (93). In breast cancer, estrogen receptor status has been associated
with variable tumor characteristics and prognoses (87). Only recently have researchers
questioned the significance of estrogen receptors in ovarian tumors, specifically the
relative expression of ERa and ERp (100, 101, 102, 103).

3.3

There are numerous unanswered questions surrounding the role and regulation of
the Fas/FasL system in the ovary and how this system may be involved in ovarian
carcinogenesis. The purpose of this study is to answer some of these questions.
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VI. Statement of Purpose and Hypothesis
Year after year, ovarian cancer claims the lives of more women in the U.S. than
any other gynecologic cancers yet many questions remain regarding this fatal disease. It
is our hypothesis that ovarian tumors may elude immunological surveillance by
inducing, via the Fas/FasL system, the apoptosis of activated lymphocytes that
would have otherwise mediated rejection of these tumors. Furthermore, we propose
that the expression of FasL in the ovary may be regulated by sex hormones,
differentially acting through various hormone receptors. The questions that we seek
to answer are the following: How is the Fas/FasL system involved in the normal and
neoplastic ovary and does this system mediate tumor escape from immune surveillance?
Do sex hormones regulate the expression of FasL in the ovary? Does the differential
expression of estrogen receptor subtypes correspond to ovarian carcinogenesis?
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VII. Methods
I actively performed the following methods described below in the laboratory of
Gil Mor, M.D., Ph.D or Eva Sapi, Ph.D: Acquisition and storage of all clinical material;
all immunohistochemistry for Fas, FasL, and cytokeratin; all preparation of RNA and
protein using TRIzol®; all RT-PCRs and Western Blots (excluding the estrous cycle);
and all hormonal studies with both organ and cell cultures. The author did not perform
the TUNEL assays or the rat experiment.
From my work, I have written several articles and abstracts that were edited and
reviewed by Gil Mor, Tom Rutherford, and/or Eva Sapi. Those that have been accepted
for publication include:
Rutherford, T., Brown, W.D., Sapi E., Aschkenazi S., Munoz, A., Verwer, K.M.A., Naftolin, F.,
Mor, G. 2000. Absence of estrogen receptor-^ expression in metastatic ovarian cancer.
Obstetrics and Gynecology. In press.
Sapi, E., Brown, W.O., Aschenkenazy, S., Tartaro, K., Lim, C., Munoz, A., Kacinski, B.M.
Rutherford, T., Mor, G. 2000. Regulation of Fas Ligand Expression by Estrogen in Normal
Ovary. International Journal of Cancer. Submitted.
Rutherford, T., Sapi, E., Brown, W., Verwer, K, Munoz, A., Mor, G. 2000. Fas and Fas
Ligand Expression in Normal and Pathologic Ovarian Tissue. Society for Gynecologic
Investigation (Abstr).
Brown, W., Mor, G., Rutherford, T., Tartaro, K., Sapi, E. 2000. Fas Ligand Expression Is
Regulated by Estrogens in Normal and Neoplastic Ovarian Epithelia. Society for
Gynecologic Investigation. (Abstr).
Brown, W.D., Sapi, E., Verwer, K.M.A., Mor, G. 1999. Fas Ligand Regulation in an
Ovarian Organ Culture System:Implications for Ovarian Cancer. Reproductive
Immunology. #P-10-NI-5. (Abstr.).
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VILA.

Clinical Material - Human Ovarian Tissue Specimens
Ovarian specimens were obtained from patients at the time of surgery in the

Department of Obstetrics and Gynecology, Yale University School of Medicine (HIC
#10425). The tissue was divided and then a portion was transported in DMEM for later
use in organ culture, snap-frozen in liquid nitrogen and stored at -70°C, and sent for
histologic examination. Primary tumor and metastatic tumor were obtained from
unmatched patients. Two of the primary and metastatic tumors were matched.

VII.B.

,

Immnohistochemistry (IHC) for FasL, Fas and Cytokeratin
Detection of FasL and Fas expression was performed using an anti-human FasL

rabbit polyclonal antibody and a mouse monoclonal anti-human Fas antibody, (clones N20 and B-10 respectively, Santa Cruz Biotechnology, Santa Cruz, CA). Detection of
cytokeratin positive cells was performed using mouse anti-human monoclonal antibodies.
All antibodies were added to dilution buffers consisting of PBS, 0.1% saponin, and 1%
BSA before application to slides (50).
Following surgical removal or organ culture, ovary specimens were fixed in 4%
paraformaldehyde and paraffin embedded using standard procedures. Five micrometer
sections were deparaffinized using graded xylene and ethanol, and the endogenous
peroxidase activity of the cells was quenched using 2% hydrogen peroxide in methanol
for 30 minutes. The sections were then rehydrated through graded ethanol and washed
with phosphate-buffered saline (PBS) for 5 minutes. Slides were incubated first with
diluted whole goat serum (1:200, Organon Teknika Corp, Westchester, PA) for FasL and
with diluted normal horse serum (1:200, Vector Laboratories, Burlingame, CA) for Fas
and cytokeratin for 20 minutes at room temperature. Then they were incubated with
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primary antibody overnight at 4°C in a humidified chamber (104). Slides were then
rinsed with 1% Triton-PBS and washed with PBS for 15 minutes. Slides were incubated
with biotin-conjugated goat anti-rabbit IgG (1:100, Vector Laboratories, Burlingame,
CA) for FasL or with biotin-conjugated horse anti-mouse IgG (1:200, Vector
Laboratories, Burlingame, CA) for Fas and cytokeratin for one hour and rinsed again in
PBS for 10 minutes. Immunoperoxidase staining was carried out using Vectastain ABC
(Vector Laboratories, Burlingame, CA) and 3’3-diaminobenzidine (DAB) HC1
peroxidase substrate kits (Vector Laboratories, Burlingame, CA), following the
manufacturer’s instructions. Before development with DAB, slides were placed in 0.25%
Triton for 30 seconds. After DAB development was completed (4-7 minutes) slides were
washed for 5 minutes in water, counterstained with Harris hematoxalin solution (7.5g/L,
Sigma, St. Louis, MO), and mounted (Permount, Fischer Scientific, Fair Lawn, NJ).

VII. C.

In situ 3’ End Labeling of DNA for Cell Death Detection
The presence in ovary tissue sections of single strand DNA breaks indicating

apoptosis was assessed using the TUNEL technique (In Situ Cell Death Detection Kit,
Fluorescent, Boehringer Manneheim, Indianapolis, IN) according to the manufacturer’s
instructions. Briefly, following deparaffmization and rehydration, slides were incubated
with proteinase K (20mg/ml in lOmM Tris/HCL, pH 7.4) for 30 minutes at 37°C.
Samples were then treated with terminal deoxynucleotidyl transferase enzyme for 60
minutes at 37°C in the dark. After washing with PBS, an alkaline phosphataseantifluorescein antibody was added and nitro-blue-tetrazolium alkaline phosphatase kit
(Vector) was used for color development. The TUNEL assays were performed by Eva
Sapi.
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VII. D.

Preparation of Total RNA and Protein Samples for RT-PCR
and Western Blot Analysis
Total RNA and protein were prepared from HEY cells, from ovarian organ

culture tissue, and from frozen ovarian surgical specimens using TRIzol® reagent
(GIBCO BRL, Gaithersburg, MD) according to manufacturer’s instructions. This
method allows for extraction of RNA and protein from the same samples. Protein
concentrations were measured by the BCA Protein Assay (Pierce), according to the
manufacturer's instructions.

VILE.

ReverseTranscription-PolymeraseChainReaction (RT-PCR)
Analysis
While RT-PCR is considered to only be semiquantitative, we have characterized

each system such that the reaction does not occur at the plateau phase. In addition each
RT-PCR is also performed for p-actin, which is constitutively expressed. In doing so, we
are able to compare the ratio of p-actin to the experimental bands to help quantify the
results.
RT-PCR was performed using the RT-PCR kit from Pharmacia BioTech
(Piscataway, NJ), according to the manufacturer’s protocol. cDNA synthesis was carried
out with 0.2 pg of pd (N)6 and 5 pg of total RNA. Seven pi of the cDNA was then put in
a reaction mix for PCR. The reaction mix consisted of 15 pmol of each primer, 5 pi PCR
Buffer (10X), 2 pi Rediload, 2 mM MgCl2, and 2.5 Units Taq polymerase (Gibco, BRL).
The PCR reaction mix was then thermal-cycled on a Perkin-Elmer Thermalcycler for the
indicated cycle programs.
The primers used for amplification of human FasL have been recently described
(75) and have the following sequence: upstream 5’-
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ATAGGATCCATGTTTCTGCTCCTTCCACCTACAGAAGGA-3’ and downstream
5 ’-ATAG AATTCTG ACCAAGAG AGAGCTCAGATACGTTG AC-3 ’.
The human Fas primers, described by Otsuki et al are as follows: forward
5 ’-AAGG AGT AC AC AG AC A AAGCCC-3 ’ and reverse 5’AAGAAGAAGACAAAGCCACCC-3’ (105). Each PCR cycle consisted of the
following: a denaturation step at 94°C, for 30 seconds, annealing at 52°C (for FasL) or at
57°C (for Fas) for 30 seconds, and elongation at 72°C for 1 minute for 10 cycles,
followed by 35 cycles modified by a cumulative 5 second increase of extension time per
cycle.
In order to quantify the ratio of ERa:ERp expression we amplified both receptors
in the same sample using one primer common for both receptors and one specific for
each receptor type. The principle of this approach has been previously described by
Pujol et al (103). This competitive PCR is possible due to the homology between the two
receptors, and involves the use of 3 separate primers: 5’ sense oligonucleotide was 5’AAGAGCTGCCAGGCCTGCC-3’, 3’antisense for ER-a was 5’TTGGCAGCTCTCATGTCTCC-3’, and the 3’ antisense oligonucleotide for ER-p was
5’-GCGCACTGGGGCGGCTGATCA-3\ 25 cycles: 94°C 30 sec, 62°C 30 sec, 72°C 1
min. All of the PCR products were analyzed on a TAE 1% agarose gel with ethidiumbromide.
The amplified PCR products were electrophoresed on a 1-2% agarose gel and
visualized with ethidium bromide (2pg/70-ml gel) under UV light. Images of the gels
were input into a computer through a video camera (Eagle Eye). The resulting digitized
images were used for densitometeric analysis of the appropriate bands. The intensity of
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each band was normalized against its corresponding B-actin band in order to compare
values between samples.

VII. F.

Western Blot Analysis
Proteins were separated by SDS-PAGE using 10% polyacrylamide gels. Twenty

pg of total cellular protein was loaded per well and run at 80V for 3 hours. The proteins
were then transferred to nitrocellulose membranes at 32V overnight. The membranes
were washed with ddthO and stained with Ponceau Red to ensure efficient transfer and
equivalent loading of proteins. The membranes were destained with 0.5N NaOH and
blocked with 5% milk for 1 hour. The blots were first incubated with the primary
antibody (FasL monoclonal antibody, clone 33, Transduction Laboratories, Lexington,
KY) at 1:1000 dilution for 1 hour. The primary antibody for Fas, a polyclonal antibody,
(M-20, Santa Cruz Biotechnology, Santa Cruz, CA) was diluted at 1:500 for 1 hour. ERa
antibody (NCL-ER-611 Novocastra) was diluted at 1:50 and incubated for 4 hours, while
ERp antibody (Ab-1 Calbiochem) was diluted at 1:500 and incubated for 1 hour. After
washing with PBS-Tween, the membranes were incubated with the secondary antibody,
peroxidase labeled horse anti-mouse gamma globulin (Vector Laboratories, Burlingame,
CA) for 1 hour for the FasL membrane or for 4 hours with the Fas membrane. The
antibodies were visualized by developing with the T'MB Peroxidase substrate kit (Vector
Laboratories, Burlingame, CA). The intensity of the bands was analyzed by densitometry
and standardized against the total amount of protein present in the gel after staining with
Coomassie blue using a digital imaging analysis system (AlphaEase, Alpha Innotech
Corporation, San Leandro, CA, USA).
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VI1.G.

Ovarian Organ Culture
Organ culture is a relatively new technique in which surgical tissue specimens are

maintained in short term culture for experimental purposes. Because this method is in its
infancy, it is not currently accepted by all scientists, and therefore continues to undergo
further exploration.
Ovarian organ culture was performed, with few modifications, as previously
described by Sapi et al. in which they cultured breast tissue (104). To monitor cellular
proliferation, they performed immunohistochemical studies on the paraffin sections of the
tissues for a cell cycle protein, Ki67. The sections stained positively for Ki67,
demonstrating active cellular proliferation in the cultured tissues, thus showing the
continued growth of the cultured tissue.
Thus, human ovary biopsy tissue was obtained from normal cycling women (less
than 50 years old) who had undergone surgery at Yale-New Haven Hospital for benign
conditions or for prophylaxis because of high risk for ovarian carcinoma. Immediately
after excision, the tissue was washed with minimal essential medium, DMEM (Life
Technologies, Grand Island, NY) supplemented with antibiotics and was dissected free of
necrotic tissue. Under a sterile hood and using sterile instruments, each specimen was
then cut into pieces approximately 1-2 mm3 and then washed in PBS. 20 of these explants
were then immersed in 5 ml of DMEM F12 without phenol red supplemented with 1%
charcoal-stripped serum (to avoid steroid contaminants) and epidermal growth factor
(lOOng/ml) in 6-well culture dishes. For hormonal studies, the culture media contained
o

10" M 17 B-estradiol, determined by dose response studies in the physiologic range to be
the most effective concentration of estrogen (Sigma Chemical Co., St. Louis, MO). For
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chemoprevention studies, culture media contained 10'7M 4-hydroxy-tamoxifen (Sigma
Chemical Co, St. Louis, MO). Cultures were then incubated at 37°C in a 5% CO2
incubator on a shaking platform for 7-8 days, as the breast organ cultures were originally
characterized. The culture media was renewed every 2 days. As a control, one sample
was cultured without additional chemicals. The cultured tissues were then fixed in 4%
paraformaldehyde for 6 hours, embedded in paraffin, and sectioned at 5pm.

VII. H.

Cell Lines

HEY cells were obtained from the American Type Culture Collection (Rockville,
MD) and cultured in McCoy’s media supplemented with 5% fetal bovine serum (Life
Technologies, Grand Island, NY) and with antibiotics/antimycotics. The HEY cell line
was propagated in Dulbecco’s modified essential medium (DMEM) Ham’s F12 medium
supplemented with 1% calf bovine serum. The cell line was cultured at 37°C humidified
chamber with 5% CO2 in air.
Cells were passed by standard methods of trypsinization, grown in 75 ml flasks,
and allowed to replicate to 80% confluence before experiments were performed.

VII. I.

In Vitro Hormonal Studies
HEY cells were incubated in serum-free, phenol red-free media for 24 hours

before the addition of hormones/antihormones. Treatments were carried out in serumQ

free, phenol red-free media supplemented with 10‘ M (3-estradiol (Sigma Chemical Co.,
St. Louis, MO), 10'7 M tamoxifen (Sigma Chemical Co., St. Louis, MO), or both
treatments for three, six, or 24 hours. A sample with no additional chemicals served as a
control. After the appropriate treatment times, the media was removed from each 75 ml
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tissue culture flask and replaced with 7.5 ml of TRIzol® (GIBCO BRL, Gaithersburg,
MD). RNA and protein were isolated following manufacturer’s instructions and analyzed
using RT-PCR and Western Blot Analysis, respectively.

VII. J.

Animal Experiment-Specimens from Rats
All studies involving animals were approved by Yale Institutional Review Boards

for Animal Care or for Human Experimentation. Animals were evaluated by vaginal
smears during three consecutive cycles. Those that showed regular cycling were
sacrificed in the morning, following deep ether anesthesia. Each ovary specimen was
excised and frozen in liquid nitrogen for RNA and protein extraction, or fixed in 4%
freshly made paraformaldehyde and paraffin-embedded for immunohistochemistry.
Tissue blocks were stored at room temperature until 5 pm sections were cut and mounted.
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VIII. Results

VIII.A. Fas/FasL in the Normal and Neoplastic Ovary
VIII. A. L

fmnuinohistochemicaf Localization of Fast in Normal
Human Ovarian Tissue
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Figure 6B. A normal human

ovarian follicle

ovanan follicle

stained for FasL

stained for Fas.

Biotechnology, Santa Cruz, CA). The normal human ovary shows weak

immunoreactivity for FasL in the granulosa layer of the follicles (Fig. 6A) and in some
prominent inclusion cysts (Fig. 7A), as determined by colocalization of cytokeratin (Fig.
10). These inclusion cysts stain most intensely in the preneoplastic areas where the
epithelial layer has lost its capacity to grow as a monolayer. The ovarian stroma appears
to be negative for FasL, aside from the occasional macrophage within the stroma.
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VIIf. A.2,

Immunohistochemical Localization of Fast in Malignant and
in Metastatic Human Ovarian Tissue
While normal human
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of human ovarian tumors shows

Figure 8B Localization of FasL in

primary ovarian cancer.

metastatic ovarian cancer.

discrete, intense staining in the clusters of neoplastic cells, including both cytoplasmic
and membranal distributions (Fig. 8A). Sections of peritoneal metastases were examined
also and were found to be strongly positive for FasL within the neoplastic implants
throughout the peritoneal tissue (Fig. 8B).

VIILA.3.

Immunohistochemical Localization of Fas in Normal,
Malignant, and Metastatic Human Ovarian Tissue

As with FasL, paraffin sections of normal and metastatic ovarian tissue were
studied for the presence of F as using a
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Localization of Fas in metastatic ovarian
cancer.

moderately immunoreactive for Fas while the follicles are not (Fig. 6B). The metastatic
implants were weakly positive for Fas (Fig. 9), but Fas staining was only detectable in
normal tissue in the inclusion cysts (Fig. 7B), corresponding to the areas of FasL
expression in inclusion cysts.

46

VIII.A.4.

In situ Cell Death Detection-Terminal Deoxy (d)-UTP Nick
End-Labeling (TUNEL)

To determine the
FAS

FAS LIGAND

APOPTOTIC CELLS

CYTOKERATIN

possible role of Fas and FasL
coexpression in the induction
of cell death of epithelial cells
lining inclusion cysts, we
studied the presence of
apoptosis in these ovarian
structures. Apoptotic cells
were detected by staining of
DNA fragments with the
TUNEL technique. TUNEL Figure 10. Localization of Fas/FasL and cytokeratin compared to location of

stained nuclei were mainly

_apoptosis._

found in the cells lining the inclusion cysts where Fas and FasL are colocalized (Fig. 10).
No, or very few, apoptotic nuclei were detected within the stroma surrounding these
cysts. Further characterization of these cells with anticytokeratin antibody identified
these apoptotic cells as epithelial cells.

VIII. A. 5.

Expression of FasL mRNA in Normal, Malignant, and
Metastatic Human Ovarian Tissue

To confirm the results obtained from the immunohistochemical studies, we then
evaluated the expression of FasL mRNA in normal, primary malignant, and metastatic
human ovarian tissue obtained from surgical specimens. Total RNA was extracted and
tested using RT-PCR. We found that normal ovary expresses a weak amount of FasL,
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while primary ovarian tumors express a
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variable amount of FasL. Upon analysis
of the metastatic ovarian tumor RNA, we

Figure 11. Expression of FasL mRNA in normal ovary.
primary ovarian cancer, and metastatic ovarian
cancer.

found this tissue to consistently express
FasL at extremely high levels compared to the other tissues (Fig. 11).

VIILA.6.

Expression of FasL Protein in Normal, Malignant, and
Metastatic Human Ovarian Tissue

In addition to examining the RNA of normal, primary malignant, and metastatic
ovarian tissue from surgical specimens, we also compared the levels of FasL protein
N

M

expression among these samples. As with the

T

RNA, there appears to be a progression of
FasL

» w ...

«*«».•

37-kDa

increasing FasL protein expression as the tissue
Figure 12. Expression of FasL protein in normal
ovary, primary ovarian cancer, and

becomes more aggressive in nature. The primary

metastatic ovarian cancer.

ovarian tumor tissue expresses more FasL than the normal tissue, while the metastatic
tissue expresses the largest amount (Fig. 12). Interestingly, the metastatic tissues are the
only samples that demonstrate expression of soluble FasL upon Western Blot analysis
(Data not shown).
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VIII.B. Hormonal Regulation of FasL

VIII. B. L

FasL Expression During the Normal Rat Cycle

In order to evaluate the effect of hormonal changes in the ovary on FasL
expression, we extracted protein from
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the rat ovary in each stage of the
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estrous cycle. Western blot analysis of

FasL-►

these proteins showed dramatic

Figure 13. Expression of FasL protein in rat ovary throughout the
cycle.

fluctuations in FasL expression throughout the cycle. The highest levels of FasL protein
expression were detected during the estrous phase, followed in decreasing order by
metestrous and diestrous phases. FasL protein expression was not detected during
proestrous (Fig. 13).

VII LB. 2.

Estrogen Regulation of FasL Expression in Normal Ovarian
Tissues

We investigated the hormonal regulation of FasL expression in normal human
ovarian tissue using an organ culture system. FasL mRNA and protein expression
increases under the influence of estrogen, as determined by RT-PCR and Western Blot
analysis (Fig. 14A, 14B). Furthermore, we found by IHC of paraffin sections that this
increase in FasL is localized to the cells immediately surrounding the follicles in the
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granulosa layer (Fig. 15). However,
+Estrogen

Control

not every ovary responded to
FasL

estrogen treatment. In some of our
organ cultures' slides, we did not
detect an increase in FasL in

FasL

inclusion cysts following estrogen
treatment. This lack of response
seems to be related to the level of

Fas

expression. Thus, there was no
increase in FasL expression in the
group receiving treatment as
compared to the inclusion cysts in
the control cultures if they were

Figure 15. Effect of estrogen administration on Fas and FasL
immunoreactivity m human ovarian organ culture

already expressing high amounts of

immunohistochemistry.

FasL (Data not shown).

VIII. B. 3.

Estrogen Regulation of Fas Expression in Normal Ovarian
Tissues

We also examined the role of estrogen stimulation in the regulation of Fas
expression in human ovarian organ cultures by immunohistochemical analysis (Fig. 15).
Estrogen administration did not have any effect on Fas expression suggesting that Fas
expression is not under direct control of estrogen. .
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VIII.B.4.

Estrogen Regulation of FasL in Ovarian Cancer Cell Line
(HEY)

In addition to examining FasL regulation in organ cultures, we also evaluated the
effect of estrogen on ovarian cancer cell lines. Similar to our results reported for the
whole tissue, we found that FasL expression in tumor cells is susceptible to hormonal
regulation.
In the human ovarian epithelial carcinoma cell line, HEY, estrogen increases FasL
mRNA expression, demonstrated by RT-PCR (Fig. 16). When HEY cells were treated
with estrogen at different time intervals,

MM

C

E3

E6

E24

a peak in FasL mRNA expression was
detected after 6 hours of estrogen

Figure 16. Estrogen regulation of FasL mRNA expression in
HEY ovarian cancer cell line.

treatment.
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VIII. B. 5.

Effect of Tamoxifen on FasL Expression in Normal Ovarian
Tissue

In order to determine that the effect of estrogen on FasL expression was estrogenreceptor mediated we studied the effects of Tamoxifen on FasL expression in ovary organ
cultures. When we examined the ovarian tissue cultured with Tamoxifen, we found a
decrease in FasL mRNA and protein expression (Fig. 14A, 14B). This difference was not
apparent, however, under immunohistochemical analysis (Data not shown).

VIII.B. 6.

Effect of Tamoxifen on FasL Expression in Ovarian Cancer
Cell Line (HEY)

Tamoxifen had an agonist effect on FasL expression in HEY cells as determined
by RT-PCR analysis. Similar to
estrogen, there was a gradual
increase in FasL expression.
Figure 17. Effect of tamoxifen and combination effect of estrogen and tamoxifen
_on FasL mRNA expression in HEY ovarian cancer cell lme._

peaking at 6 hours of tamoxifen
stimulation (Fig. 17).
A synergistic effect of estrogen and tamoxifen was observed. Thus, the addition
of both hormones together induce FasL expression levels higher than those observed with
estrogen or tamoxifen alone (Fig. 17).

VIII.B. 7.

Effect of Estrogen and Tamoxifen on Fas Expression in
Ovarian Cancer Cell Line (HEY)
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Estrogen regulation of Fas

Figure 18B. Effect of tamoxifen and

mRNA expression in HEY

combination effect of estrogen

ovarian cancer cell line.

and tamoxifen on Fas mRNA
expression in HEY ovarian
cancer cell line.
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When we analyzed the effect of estrogen and tamoxifen on HEY cells' Fas
expression no effects were found. Estrogen had no effect on Fas expression at 3, 6, and
24 hours. Tamoxifen alone or together with estrogen had no apparent effect on the
expression of Fas in HEY cells either (Fig. 18A, 18B).

VIII.C. ER Alpha and Beta Expression in the Ovary
VIILC.l.

mRNA Expression of ER alpha and beta in Normal Human
Ovarian Tissue, Primary Human Ovarian Tumor, and
Metastatic Disease

In order to study the potential role of the two ERs in ovarian carcinogenesis, we
evaluated the relative levels of ER-a and ER-P mRNA expression in 9 normal ovarian
samples, 8 primary ovarian cancers and 8 metastatic ovarian cancers. Details of each
patient's age and histologic diagnosis are described in Table 2.
In the non-neoplastic
ovary, both estrogen receptors
alpha and beta are expressed
although ERp is the
predominant ER subtype.
Quantification of the ERa:ERp
ratio showed a —1:2
relationship. When we further
analyzed ER expression in primary ovarian tumors, a high variation in the ER mRNA
expression and ratio was detected between the different samples (Fig. 19). As shown in
Table 2, 37.5 % of the cases expressed both ERa and ER(3 although the level of
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expression for ERa was higher than ERfl. 37.5% primary tumors expressed only ERa
and 25% had only ERp (Table 2).
On the other hand, metastatic tumors expressed only ERa mRNA with complete
absence of ERf3 mRNA. In one case, expression of ERa and ERp were identified
although ERf3 mRNA level was markedly lower than ERa (data not shown). However,
this sample was, according to the pathologic diagnostic, heterologous malignant mixed
Mullarian tumor.

VIII.C.2.

Protein Expression of ER alpha and beta in Normal Human
Ovarian Tissue, Primary Human Ovarian Tumor, and
Metastatic Disease

In order to evaluate if the ERa
$
and ER^ protein was expressed in the
human ovarian tissues, protein extracted
from the same cases were analyzed by
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Laboratories, Claremont Place, UK) and
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a polyclonal antibody for ERp (clone
Figure 20. Western Blot of ERa and ERp protein

AB-1, Oncogene Research Products,

_expression in human ovarian samples.

Cambridge MA). The same results as described for the RNA were found with the
western blot analyses. Thus, ERa and ERp were present in normal ovary and primary
tumor. Metastatic ovarian tumors were characterized by the expression of high levels of
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only ERa and the complete absence of ERp protein expression (Fig. 20). Normal human
endometrium was included as positive control for ERa. The normal endometrium
expresses high levels of ERa and low levels of ERfT
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IX. Discussion

IX.A. Fas/FasL in the Normal and Neoplastic Ovary
We began our investigation of Fas/FasL and the ovary by defining the presence
and location of FasL in the normal human ovary. Our results indicate that the normal
human ovary expresses FasL in two main areas - in the granulosa layer of the follicle and
in the inclusion cysts (Fig. 6A, 7A).
We found that the granulosa layer of the follicle is weakly immunoreactive for
FasL. This is consistent with previous studies reporting the presence of FasL in follicular
cells of the ovary (61, 62, 63). In the murine ovarian follicle, FasL has been localized to
the granulosa cells, while Fas seems to be restricted to the oocyte (61). Others have
found the opposite in the rat ovary with the oocyte expressing FasL and the granulosa
expressing Fas (62). Although there is no consensus on the exact cellular distribution of
FasL in the human ovary, it is clear that the Fas/FasL system is present and does operate
in some capacity.
Female reproductive tissues such as the ovary, breasts, and uterus undergo a
normal, periodic cycle, resulting in cellular proliferation and death. In the ovary, this is
exemplified by follicular growth and atresia. The ovarian cycle consists of follicular and
luteal phases (Fig. 3), during which a single successful follicle undergoes ovulation and
becomes a corpus luteum. Meanwhile, the unsuccessful follicles undergo atresia. It has
been shown that this cellular reduction in the ovary occurs via apoptotic mechanisms
(55). Apoptosis is influenced by a wide variety of stimuli. Among the known “death
receptors” (TNF-R1, DR-3, TRAIL-R1, and 2), Fas is one of the most important.
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Interaction between Fas and its ligand (FasL) induces receptor trimerization, which in
turn results in recruitment of the adaptor protein FADD and activation of caspases, which
leads to irreversible cell damage and death (Fig. 1) (37). Our results suggest that
Fas/FasL is one of the underlying mechanisms of apoptosis in the cycling ovary.
A second role for the Fas/FasL system may be in post-ovulatory epithelial repair.
In the ovarian surface epithelium, we found a moderate amount of both Fas and FasL.
This is in agreement with a study showing that the addition of Fas mAb to enriched
cultures of mouse OSE immediately stimulates apoptosis, suggesting the presence of
FasL in the surface epithelium. These cells on the surface of the preovulatory follicle
exhibit programmed cell death in preparation for ovulation (65); therefore, the Fas/FasL
system could serve as the mechanism by which these cells undergo apoptosis and allow
for release of the ovum.
During the postovulatory repair process, it is thought that proliferating epithelial
cells invaginate, forming clefts, or become entrapped in the stroma, forming cysts (16).
Within these structures, the cells are eliminated via apoptosis. We found co-localization
of Fas and FasL in the epithelial cells lining these cysts. Furthermore, TUN EL assays of
these same sections demonstrated apoptotic cells along this border of co-expression (Fig.
10), indicating a role for this system in controlling epithelial cell propagation. Although
Fas and FasL appear to be distributed within the stroma as well, apoptosis seems to occur
only along the epithelial areas of coexpression. This could be due to increasingly
membranal expression of the molecules as they near the surface, allowing for more
interaction between the receptor and its ligand.
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In addition to the above-mentioned roles for Fas/FasL in the normal ovary, it may
also serve as an immunological barrier. As Sertoli cells express FasL to defend the
testicle from immunological invasion (38), perhaps the FasL-expressing granulosa cells
surrounding each oocyte serve a similar function of immune protection. FasL expression
may enable the follicular cells encircling the oocyte to kill invading immune cells,
minimizing dangerous inflammatory reactions in this vital area. Interestingly, previous
studies have shown that the age of an organ may affect its immune privileged status
(107). They found that transplanted testicular tissue from young mice can resist rejection
whereas tissue from adult mice may be rejected. If age is found to similarly downregulate FasL expression in the ovary, this could render the ova susceptible to immune
invasion and possibly be a factor in the initiation of menopause.
While examining Fas and FasL expression in inclusion cysts, we also observed a
disproportionately strong immunoreactivity for FasL in those cysts that exhibited
abnormal growth patterns, such as those developing into an epithelial cell mass rather
than a monolayer. While Fas expression remained unchanged, FasL appeared to be
overexpressed in these areas. Because inclusion cysts are exposed to concentrated levels
of proliferative stimuli within the ovarian stroma, there is a high mitotic rate and a high
probability of cellular mutation and clonal propagation (16), especially if that mutation
disables a system of apoptosis such as Fas/FasL. This imbalance in Fas and FasL
expression may indicate an early stage of neoplastic transformation. The over-expression
of FasL by epithelial cells could serve as the mechanism by which abnormal ovarian
surface epithelium escape immune surveillance, allowing tumor growth and metastasis.
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This theory is supported by the subsequent observation that FasL expression in
the human ovary increases in direct proportion to the degree of malignancy while Fas
expression remains stable (Table 1). Upon light microscopic examination of normal
human ovary tissue, primary ovarian cancer, and metastatic ovarian cancer sections
stained for Fas and FasL, we found a dramatically different staining pattern among the
various FasL samples (Fig. 8A, 8B) and no change among the Fas samples (Fig. 9). As
compared to the normal ovary, an increase in FasL intensity was discovered in the
primary tumor, and a wider distribution and even greater intensity was encountered in the
metastatic disease. RT-PCR(Fig. 11) and Western blot analyses (Fig. 12) confirmed
these results as they revealed enlarging FasL bands, particularly in the metastatic disease
samples. The distribution and intensity of Fas expression among the tissues remained at
a constant, low level as seen on IHC.
While FasL expression has been shown to be a major factor in immune privilege
(Fig. 2), this same mechanism of immune evasion has been described in multiple cancers
(42). Our results indicate that it may apply to ovarian carcinoma as well. If Fasexpressing activated lymphocytes invade an ovarian neoplasm that overexpresses FasL,
the lymphocytes will undergo apoptosis induced by the interaction between Fas and
FasL, enabling the cancerous cells to proliferate and metastasize.

IX.B. Hormonal Regulation of FasL
Once we established the presence of Fas and FasL in the ovary, we studied the
physiological role of the Fas/FasL system in normal ovarian function and the factors that
may regulate its expression and function. In the present study we demonstrate that FasL
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expression is hormonally dependent and that estrogen has a direct effect on FasL
expression.
The normal ovary both synthesizes and responds to hormones throughout the
hormonal ovarian cycle; therefore, we speculated that if it is hormonally regulated, FasL
expression within the ovary should also change during the cycle. Indeed, FasL
expression fluctuates in accordance with the stage of the cycle (Fig. 13).
In order to identify the hormone(s) responsible for this phenomenon, we studied
the effect of estrogen on FasL expression using two in vitro systems, an ovarian organ
culture and a cell culture. Organ culture is a novel means of culturing tissue from
surgical specimens for short-term experiments (104). In using this system, we were able
to administer various sex hormones to pieces of ovarian tissue and observe their effects
on the tissue as a whole. This system more closely resembles that of the human body
than cell culture since different cell types (granulosa, theca, oocyte, stroma epithelial
cells) are allowed to interact and affect surrounding cells as they would in vivo. A
preculture control and the cultured control samples serve as comparisons. At the end of
the experiment, the tissue may be put into paraffin blocks for immunohistochemical
studies or processed for RNA and protein analysis.
We cultured 20 ovaries in this manner in the presence of 17-P-estradiol (10'8 M)
and found that estrogen upregulates the expression of FasL. This is in accord with prior
studies on estrogen and FasL in the breast in which an ERE-like motif was reported in the
promotor region of the human FasL gene (82). In this study, estrogen increases FasL
expression in the MCF-7 breast cancer cell line. In our study, both the preculture and
culture controls stained similar to the normal ovarian tissue obtained directly from
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surgical removal, with FasL present in the granulosa layer and in inclusion cysts (Fig.
15). With 17-p-estradiol administration, IHC studies demonstrated an increased FasL
immunoreactivity in the granulosa layers of the follicles, suggesting an upregulation of
FasL expression with estrogen addition (Fig. 15). At the RNA and protein levels, this
same effect was detected. Analysis of the bands on RT-PCR and Western blot using a
densitometer revealed a significant increase in FasL expression after estrogen treatment
as compared to the control group (Fig. 14A, 14B).
When we examined the same sections for effects of estrogen on inclusion cysts,
we found no difference in FasL expression between the treated and untreated tissues.
Because FasL, along with Fas, is expressed at a continually high level in inclusion cysts
to mediate apoptosis and assist in entrapped epithelial cell removal, estrogen
administration cannot further increase FasL expression.
In order to determine the effect of estrogen and tamoxifen on ovarian epithelial
cells in isolation, we studied the epithelial ovarian cancer cell line HEY. Previous
investigators had reported a complete lack of estrogen receptors in the HEY cell line
which was inconsistent with our findings (102). Our cultures of HEY cells have
apparently evolved to have different ER characteristics and they express ERf5 mRNA as
determined by RT-PCR. Therefore, they theoretically are able to respond to estrogen
stimulation. This cell line also displays a small baseline amount of FasL when grown
under control conditions, making it an adequate model for determining the effect of
estrogen on FasL expression in an ovarian cancer cell lines.
Our results show that the HEY cells respond to estrogen with increased FasL
expression just as the organ culture tissue did and as the previously reported MCF-7
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breast cancer cell line (82). This estrogenic effect was apparent as early as 3h of
treatment, with a peak in FasL mRNA expression at 6 hours of estrogen treatment (Fig.
16). On the other hand, estrogen had no effect on Fas expression. Fas mRNA levels
were similar throughout the time course of estrogen treatment (Fig. 18A).
Throughout the body, the overall effect of estrogen is mitogenic, stimulating
growth and proliferation of tissues. In contrast, the estrogen agonist/antagonist tamoxifen
has variable effects, depending on tissue type (86). Tamoxifen has been reported to have
an antiestrogen effect on breast tissue and is, therefore, used in the treatment and
prevention of estrogen-responsive breast cancers.
In contrast, ovarian cancer patients have not had the same success with tamoxifen
treatment with only a 7-18% response rate (90). Some have postulated that ovarian tissue
is hormonally unresponsive; however, the majority of ovarian cancers express estrogen
receptors (89). We found differing results between organ cultured ovarian tissue and
HEY ovarian carcinoma cells. When samples of the whole ovary were cultured in vitro
and treated with tamoxifen, the effect was different than the previously reported
inhibitory effect of tamoxifen on MCF-7 breast cancer cells (82). Moreover, the effect of
tamoxifen treatment on HEY cells did not oppose that of estrogen. Instead, it was
agonistic, increasing the expression of FasL mRNA over time (Fig. 17). Furthermore,
when estrogen and tamoxifen were co-administered, there was a synergistic effect, with
even greater enhancement of FasL expression than either treatment alone (Fig. 17). Fas
expression did not change with either treatment. Further studies need to be done on cell
lines that contain ERa alone and both estrogen receptors in order to determine if this
difference in tamoxifen action is ER dependent. Also, the overall effect of tamoxifen in
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the ovary may be dependent upon the interaction of the many different cell types in the
complete ovary, since the organ cultures did show a down-regulation of FasL when
incubated with tamoxifen.

IX.C. ER Alpha and Beta Expression in the Ovary
Upon learning of the role that FasL may play in ovarian carcinogenesis and after
realizing the potential influence estrogen may have on the regulation of FasL expression,
we undertook the task of characterizing the population of estrogen receptor subtypes in
the ovary and in different stages of disease. We found that the normal ovary is
characterized by the presence of both ERa and ERfL This is in agreement with previous
studies showing co-expression of ERa and p in the ovary, with ERa mRNA expression
at a lower level than ERp mRNA (102, 98, 106). The cellular distribution of ERp in
human and rodents, has been shown to be primarily in granulosa cells of small growing
and preovulatory follicles while ERa is distributed throughout the normal ovary (106).
Only recently, the ER status of normal ovarian surface epithelium (OSE) has been
reported to show the presence of ERa and ERp. After characterizing the ER status of
normal ovary, we examined the ER subtypes in primary ovarian cancer and in metastatic
disease. We demonstrate the presence of high levels of ERa mRNA expression in
metastatic ovarian carcinoma with undetectable ERp mRNA expression. This was
further confirmed by Western blot analysis showing the presence of ERa protein but not
ERp in metastatic ovarian tumor (Fig. 19, 20).
Since the majority of ovarian cancer is presumed to originate in ovarian surface
epithelium and 62.5% of the studied ovarian tumors expressed ERp (Table 2) the
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complete absence of ERji expression in metastatic ovarian cancer could represent a
characteristic of metastatic transformation. Another possibility is that cells expressing
ER(3 cannot survive in metastatic ovarian epithelial cancer.
Our work demonstrates a high variation in ER expression in primary ovarian
tumors, with a predominant characteristic change in the ERa:ERp ratio showing a higher
level of ERa than ERfJ compared to normal ovarian epithelium (Table 2). Further, we
report the absence of ERp expression at the mRNA and protein levels in metastatic
ovarian tumors. These results, together with previous studies, provide strong evidence
for an essential role of the ER type in the regulation of transformation and metastasis of
epithelial ovarian cancer.
ERa expression has been extensively studied in ovarian cancer in order to
correlate it to clinical behavior and prognosis. Despite that, no clear relationship between
ER expression and tumor histology, patient age, or outcome has been noted in epithelial
tumors (108). Of particular interest to normal ovarian physiology and malignant
transformation is the observation that malignant tissues from epithelial origin express
substantially higher levels of ERa than ERfk Recent studies have shown that the relative
levels of ERa and ER(3 are important determinants of the biological response to ER
agonists in specific target tissue and could be important in the pharmacology of
antiestrogens (109). Therefore, future studies should focus on the use of a variety of
selective estrogen receptor modulators (SERMs), including raloxifene, in the treatment of
ovarian cancer. It has been shown that estrogen induces apoptosis in neuronal-like cells
expressing ER£ but induces cell growth and proliferation in similar cells expressing both
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alpha and beta ER (110). A lack of ERp in malignant ovarian tissue could represent a
state of resistance to inhibitory pathways.
In the primary ovarian tumors analyzed, we found a wide range in phenotypic ER
expression with decreasing levels of ERj3 expression being the only common
denominator. These findings have two important implications. One is that the balance
between ERa and ERf3 receptors may be imperative to maintain normal cellular function.
The second implication may be that, as the level of the ERp decreases, uncontrolled
cellular proliferation leads to a metastatic state. Therefore, the ER status could be used as
a prognostic marker of ovarian carcinogenesis.
These findings indicate that a fundamental biological difference may exist
between primary and metastatic ovarian cancer cells, which could be due to intrinsic, or
extrinsic factors regulating gene expression. Understanding these factors may furnish
insight into carcinogenesis, metastatic behavior and effects of treatment.
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IX.D. Conclusion
Epithelial ovarian cancer is a leading cause of mortality among women in the
United States, yet many questions remain regarding its etiology, prevention, detection
and treatment. We believe that many of these questions can be answered by serious
investigation into the Fas/FasL system of apoptosis and its relevance to ovarian
tumorigenesis.
In the present study, we demonstrate the presence of Fas and FasL in ovarian
tissue and offer several possible roles for the Fas/FasL system in the normal ovary. We
also identify estrogen as a key regulator of FasL expression in the ovary. Furthermore,
we demonstrate a gradient of increasing FasL expression along the pathway of cancer
development and spread, along with a changing estrogen receptor distribution. From
these observations, we conclude that a disruption in the Fas/FasL system in the ovary
may underlie ovarian carcinogenesis.
An important question in tumor immunology involves the means by which a
neoplasm is able to escape immune surveillance. We and others have demonstrated a
role for FasL in this phenomenon of immune escape. This theory holds that Fasexpressing activated lymphocytes detect and invade a tumor, they contact the FasLbearing cells of the tumor, and the Fas/FasL interaction induces cell death in the immune
cells. Thus, an imbalance between Fas and FasL, with an overexpression of FasL, could
lead to uncontrolled cellular proliferation and perhaps even to cellular transformation and
tumor growth.
Although we believe that the Fas/FasL system plays an integral part in ovarian
pathogenesis, it is likely that it represents only one of many other factors. The
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development of ovarian carcinoma is the end result of a complex multistep process
involving the complementary actions of different cancer causing genes (18), including
p53, erbB-2, K-ras, myc, and fms.
One hypothesis for ovarian transformation links the p53 and Fas/FasL pathway
(Fig. 21). The p53 gene
has been implicated in
ovarian cancer, with at
least 50% of advanced
stage ovarian cancers
demonstrating point
ILLUSION CYST

mutations (111). Recently,
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Figure 21. Model of proposed interactions among hormones, p53, and Fas/FasL in the
_ovary._

researchers have found that
a functional p53 protein is

necessary for proper Fas/FasL activity. Bennett and others found in human vascular
smooth muscle cells that p53 transiently increases surface Fas expression by transport
from the Golgi complex (112). By moving Fas to the cell surface, it allows for the
interaction of Fas with FasL, which activates the death signal, and initiates apoptosis.
Thus, through Fas transport, p53 can mediate programmed cell death.
Repetitive injury and repair of the ovarian surface epithelium occurs secondary to
continual ovulation, resulting in an increased mitotic rate and a high probability for
mutations to occur. If the p53 gene were mutated during the post-ovulatory repair
process, this would prevent Fas movement to the cell surface, would allow for the
sole expression of FasL, and would prevent the normal signal for death. If this
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abnormal cell was then exposed to a microenvironment rich in estrogen lining an
inclusion cyst within ovarian stroma, FasL would be up-regulated, further
exaggerating the Fas/FasL imbalance. The cell could then multiply without restraint
due to a lack of apoptosis, creating a lineage of apoptosis-resistant cells. In addition,
these cells would then have the capacity to evade an immune response due to their
expression of FasL; thus, setting the stage for cellular transformation, growth, and
metastasis.
By recognizing the role of Fas/FasL in the normal ovarian cycle and its potential
role in neoplastic transformation and immune escape, we can offer new insights into the
etiology of ovarian cancer. In addition, by understanding the factors that regulate this
system, we can provide new targets for preventive and therapeutic interventions.
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XI. Figure References and Legends
Figure 1._Model of internal events in apoototic cell (p. 14),
Interaction between Fas and its ligand (FasL) induces receptor trimerization,
which in turn results in recruitment of the adaptor protein FADD and activation of
caspases, which leads to irreversible cell damage and death. Model created by Gil Mor.

Figure 2._Model of Fas/FasL interaction in immune privileged tissues (p. 16).
Immune privileged tissues can prevent serious inflammatory responses through
the expression of FasL, which interacts with the Fas receptor on invading T cells and
induces apoptosis. Model created by Gil Mor.

Figure 3,_Model of cyclic changes in female reproductive tissues (p.18).
Serum hormone levels, follicular activity, and changes in the human endometrium
during the menstrual cycle. Model created by Gil Mor.

Figure 4.

Model of intracellular actions of estrogen (p.28).

Estrogen is a steroid hormone that acts on intracellular receptors to directly affect
gene transcription. Model created by Gil Mor.

Figure 5,_Model of estrogen receptors (p.31V
Comparison of the twoestrogen receptor subtypes alpha and beta. Model created
by Gil Mor.
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Figure 6,

Localization of Fas and FasL expression in normal human ovarian tissue

(P. 45).
Paraffin sections of normal human ovarian tissue were stained for FasL or Fas.

(A) A normal human ovarian follicle stained for FasL. (B) A normal human ovarian
follicle stained for Fas.

Figure 7,

Localization of Fas and FasL expression in ovarian inclusion cysts (p.45V

Paraffin sections of normal human ovarian tissue were stained for FasL or Fas.

(A) An ovarian inclusion cyst stained for FasL. (B) The same ovarian inclusion cyst
stained for Fas.

Figure 8,

Localization of FasL expression in human ovarian cancer samples (p46L

Immune staining of paraffin sections of primary ovarian tumors and metastatic
ovarian cancer. (A) Primary ovarian cancer. (B) Ovarian cancer metastatic to the
peritoneum.

Figure 9._Localization of Fas expression in human ovarian cancer samples (p.46L
Fas expression in metastatic ovarian cancer.

Figure 10.

Localization of Fas/FasL and cvtokeratin compared to location of
apoptosis (p.47).

Immune staining and TUNEL analysis of paraffin sections of human ovarian
organ culture tissue. (A, B) EHC of inclusion cysts showing FasL and Fas expression
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corresponding to cytokeratin staining (D). (C) TUNEL analysis of same area showing
apoptosis where Fas and FasL overlap. Pictures taken by Eva Sapi.

Figure 11.

Expression of FasL mRNA in normal ovary, primary ovarian cancer, and
metastatic ovarian cancer (p.48F

Reverse transcriptase-polymerase chain reactions (RT-PCR) for FasL was
performed with total RNA extracted from human ovarian tissue with various degrees of
cancer invasion. N, normal ovarian tissue, T, primary ovarian tumors, and M, metastatic
tumors, MM, molecular marker.

Figure 12.

Expression of FasL protein in normal ovary, primary ovarian cancer, and
metastatic ovarian cancer (p.48).

Western blot analysis for FasL was performed with protein samples obtained from
the same samples described in Figure 12. N, normal ovarian tissue, M, metastatic tumor,

T, primary ovarian tumor.

Figure 13.

Expression of FasL protein in rat ovary throughout the cycle (p.49Y

Western blot analysis for FasL was performed with protein samples obtained from
cycling rat ovaries, showing a variation in FasL expression in the different stages of the
cycle. Western blot and picture by Gil Mor.

Figure 14,

Effect of estrogen on FasL expression in ovarian organ culture (p.49).

(A) RT-PCR for Fas and FasL were performed with a total RNA extracted from in
vitro organ culture of human ovarian tissue. C, control tissue (no hormones), E, estrogen
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treatment, Tmx, tamoxifen treatment, E+Tmx, estrogen and tamoxifen treatment. (B)
Western Blot analysis for FasL was performed with protein samples obtained from in
vitro organ culture of human ovarian tissue. C control (no hormonal treatment), Tmx
tamoxifen treatment, E estrogen treatment, E+Tmx estrogen and tamoxifen treatment.

Figure 15.

Effect of estrogen administration on Fas and FasL immunoreactivitv in
human ovarian organ culture immunohistochemistrv (p.50).

Paraffin sections from ovarian organ cultures were studied for Fas and FasL
expression using a specific monoclonal and polyclonal antibodies, respectively. When
o

compared to the control group (A), estrogen-treated (17-p-estradiol, 10' M) human
ovarian tissue (B) undergoes an upregulation of FasL expression in follicular cells. (C),

(D) An ovary that is unresponsive to estrogen administration. There is little or no change
in Fas expression when ovarian organ cultures are treated with estrogen (E, F). Pictures
taken by Eva Sapi.

Figure 16,

Estrogen regulation of FasL mRNA expression in HEY ovarian cancer
cell line (p.51).

RT-PCR for FasL was performed with total RNA extracted from in vitro culture
of HEY cells treated with estrogen for 3, 6, and 24 hours.

Figure 17.

Effect of tamoxifen and combination effect of estrogen and tamoxifen on
FasL mRNA expression in HEY ovarian cancer cell line (p.52).

RT-PCR for FasL was performed with total RNA extracted from in vitro culture
of HEY cells incubated with tamoxifen or estrogen plus tamoxifen for 3, 6, and 24 hours.
C, control; T tamoxifen; E/T, estrogen plus tamoxifen
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Figure 18.

Effect of estrogen and tamoxifen on Fas mRNA expression in HEY
ovarian cancer cell line (p.52).

A. RT-PCR for Fas was performed with total RNA extracted from in vitro culture
of HEY cells treated with estrogen for 3, 6, and 24 hours.

B. RT-PCR for Fas was performed with total RNA extracted from in vitro culture
of HEY cells incubated with tamoxifen or estrogen plus tamoxifen for 3, 6, and 24 hours.
C, control; T tamoxifen; E/T, estrogen plus tamoxifen

Figure 19.

ERa and ERfi mRNA expression in human ovarian samples (p.53V

RT-PCR for ERa and ER|3 was performed with a total RNA extracted from
human ovarian samples. Results shown are representative of co-amplification for the
human ERa and ER(3 in: N, normal ovarian tissue, T, primary ovarian tumors, and M,
metastatic tumors, NP, normal peritoneum, MM, molecular marker. PCR products were
quantified by densitometry using a digital imaging and analysis system.

Figure 20.

Western Blot of ERa and ERB protein expression in human ovarian
samples (p.54F

Western blotting for ERa and ERp was performed with protein samples obtained
from the same tissues analyzed for RNA. Proteins were separated by SDS-PAGE using
10% polyacrilamide gels, transferred into nitrocellulose membranes and immunoblotted
with antibodies for ERa or ERp. The secondary antibody (peroxidase-labeled horse anti¬
mouse or goat anti-rabbit) was developed with TMB peroxidase substrate kit. Normal
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uterus was used as a positive control for ERa expression. Results shown are
representative of at least three experiments. (A) ERa, (B) ER|3

Figure 21.

Model of proposed interactions among hormones. p53. and Fas/FasL in
the ovary (p.67).

Under proper hormonal stimulation, a functional p53 relocates Fas from a
cytoplasmic to membranal site. Here, Fas can interact with FasL to induce apoptosis. If
not properly regulated, however. Fas may fail to move to the surface, leaving sole
expression of FasL, resulting in uncontrolled cellular growth due to failure of apoptosis.
Furthermore, any attempt made by the immune system to combat this irregularity is
thwarted when Fas-expressing T cells are induced to undergo apoptosis by the FasL
expression of the abnormal cells. This scenario demonstrates how an imbalance in Fas
and FasL expression could result in neoplastic transformation of cells, which can then
avoid immune attack. Model created by Gil Mor.
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XII. Tables
Table 1.
Classification and characteristics of Fas/FasL mRNA.

Fas

Fas Ligand

Histology

R039

(+)

(+/-)

45

R034

(+)

(+/->

47

R049

(++)

(++)

Papillary Serous, Stage LUC, Grade III

50

R018

(++)

(+/-)

Papillary Serous, Stage IIIC, Grade I

61

R031

(+++)

(-H-+)

Papillary Serous, Stage IIIC, Grade III

71

R048

(+++)

(+++)

Papillary Serous, Stage IIIB, Grade III

50

Age

Normal Ovary

Primary

Metastasis

R8

Table 2
Classification and characteristics of ER alpha and beta mRNA.

Histology

ER-a ER-p

Age

Normal Ovary
R035

(++)

(+++)

67

R036

(++)

(+++)

56

R039

(++)

(+++)

45

R034

(++)

(+++)

47

R026

(++)

(++)

80

OV17PCC

(+)

(++)

60

R07

C++)

(+++)

71

R03

(++)

(+++)

53

R020

(++>

(++)

80

R059*

(+++)

(-)

Papillary Serous, Stage IITC, Grade m

48

R049*

<+++)

(-)

Papillary Serous, Stage MB, Grade ITT

50

R053

(-)

<+)

Papillary Serous, Stage IIIC, Grade m

53

R037

<-)

<++)

Mucinous Stage IIC, Grade I

56

R018

(+++)

{++)

Papillary Serous, Stage IIIC, Grade I

61

R061

<+)

{-)

Papillary Serous, Stage IIIC, Grade III

61

R041

(++)

{++)

Papillary Serous, Stage IIIC, Grade III

66

R054

(+++)

<++)

Borderline Mucinous, Stage IA, Grade I

38

Primary Tumor

89

Metastasis
R060*

(+++)

(-)

Papillary Serous, Stage IIIC, Grade III

53

R048*

(++++)

(-)

Papillary Serous, Stage IIIB, Grade III

50

R031

(+++)

(-)

Papillary Serous, Stage IIIC, Grade III

71

R021

(++++)

(-)

Papillary Serous, Stage IIIC, Grade III

71

R058

(+++)

(-)

Papillary Serous, Stage IIIC, Grade III

48

R005

(++++)

(-)

Papillary Serous, Stage IIIC, Grade III

60

R052

(++++)

(-)

Papillary Serous, Stage IIIC, Grade III

30

R064

(++++)

(-)

Papillary Serous, Stage IV, Grade III
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* Represents match primary to metastatic tumor. Pairs R049/R048 and RO59/RO60

Table 3.
Percentage of ERa and ERp mRNA expression in normal, primary and metastatic
ovarian tumors.

Tissue

ERa alone

ERp alone

ERa/ERp

Normal

0% (0/9)

0% (0/9)

100% (9/9)

Primary Tumor

37.5% (3/8)

25% (2/8)

37.5% (3/8)

Metastasis

100% (8/8)

0% (0/8)

0% (0/8)
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